<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#x0A;" />
                    <role n="1" descr="theme (process or entity being stopped)&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>3-slice site mutations blocked of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>3-slice site mutations is more specific to distinguish between different RNA polymerases because it can block of 2 (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>3-slice site mutations is more specific to distinguish between different RNA polymerases because of 2 was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>3-slice site mutations may block of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>3-slice site mutations that specifically blocked of 2 does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0 is more specific for the distinction between different RNA polymerases, as it is able to block Memory (Mathews and Durbin, 1994), i.e., its action is independent of different initiation factors.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A0 is more specific for the distinction between different RNA polymerases, as it is able to block myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initiation factors.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A0 is more specific for the distinction between different RNA polymerases, as it is able to block the action of a recommended repressor (Mathews and Durbin, 1994), i.e., its action is independent of different initiation factors.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Alanine is more specific for the distinction between different RNA polymerases, as it can blocks the action of a postulate repressor (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Alanine is thought to block the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Alanine may block the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Alanine would block the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Antibody GR elevation in 14-3-3eta for the phosphopeptide Y553 was specific, since labelling was able to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Antibody Meloid colony formation for the phosphopeptide Y553 was specific, since labelling was able to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Antibody RNA polymerase during elongation for the phosphopeptide Y553 was specific, since labelling was able to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as labelling was blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as labelling was blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as labelling was blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, since labelling was able to be blocked by antibody to RAP1.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Antibody label for the phosphopeptide Y553 was specific, since labelling was able to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Antibody labelling for the phosphopeptide Y553 was specific, as labelling was blocked by pre-incubation of antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Antibody of 2 for the phosphopeptide Y553 was specific, since labelling was able to be blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Antibody of step II for the phosphopeptide Y553 was specific, as labelling was blocked by mutations to the 3rd place of the ear.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Antibody step II for the phosphopeptide Y553 was specific, since labelling was able to be blocked by mutations to the site of the 3rd portion.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since RNA polymerase during elongation is able to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since invasion of merozoite in vitro is able to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since invasive merozoites in vitro is able to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since step II is able to be blocked by mutations to the site of the 3rd portion.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since the action of a postulate repressor is able to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because GR elevation in 14-3-3eta is believed to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because formation of myeloid colonies is believed to be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because in vitro merozoid invasion is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because invasion of merozoites in vitro is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because labelling is believed to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because labelling is believed to be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because of step II is believed to be blocked by mutations to the 3rd place of the ear.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because step II is believed to be blocked by slice site mutations.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because the action of a postulate repressor is believed to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as Meloid colony formation was believed to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as formation of myeloid colonies was believed to be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as formation of myeloid colonies was believed to be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as invasion of merozoites in vitro was believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as labeling was believed to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as labelling was believed to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as myeloid colony formation was believed to be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as relevation of GR by 14-3-3eta was believed to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as step II was believed to be blocked by mutations of the cutting site.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as step II was believed to be blocked by mutations of the inflection site.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as the action of a postulate repressor was believed to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as the action of a prescribed repressor was believed to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as the elevation of GR in 14-3-3eta was believed to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Antibody the action of a postulate suppressor for the phosphopeptide Y553 was specific, as labelling was blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Antibody the action of a postulated repressor for the phosphopeptide Y553 was specific, as labelling was blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Antibody the action of a prescribed repressor for the phosphopeptide Y553 was specific, as labelling was blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Block Memoirs in TBST (Tris-buffered saline, 0.05% Tween-20) block 5% of beef serum albumin (for antiphosphorosine blots) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) block 5% of beef serum albumin (for antiphosphorosine blots) or skimmed milk and antibody polled.</text>
                    <arg n="1">membranes</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Block the action of a recommended repressor in TBST (Tris-buffered saline, 0.05% Tween-20) block 5% of beef serum albumin (for antiphosphorosine blots) or skimmed milk and antibody polled.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Meloid colony formation has been blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Meloid colony formation was believed to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that RNA polymerase during elongation was believed to be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that action of a prescribed repressor was believed to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that action of a prescribed repressor was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that alanine blocked action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that alanine blocked the action of a postulate repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that alanine blocked the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that alanine was able to block action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that antibody to RAP1 was able to block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies can be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies has been blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies is believed to be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies is believed to be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies is blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies will be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies would be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies would be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that greater GR in 14-3-3eta was blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that increasing GR by 14-3-3eta is believed to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation was able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that inhibition of the PU.1 function in humans CD34+ before this regulation was able to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that inhibition of translation blocked greater GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoites in vitro is believed to be blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoites in vitro was blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that label is blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labeling would be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelled is believed to be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelled was believed to be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelling can be blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelling has been blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelling is believed to be blocked by pre-incubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that labelling was blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that myeloid colony formation has been blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that of 2 could be blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that of 2 was believed to be blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that of 2 will be blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that pre-incubation of antibodies with phosphopeptide blocked labelled (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that pre-incubation of antibodies with phosphopeptide was able to block taging (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that pre-incubation of antibody with phosphopeptide blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that pre-incubation of antibody with phosphopeptide was able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that rain of GR by 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that rain of GR by 14-3-3eta was believed to be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that rain of GR by 14-3-3eta would be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that relevation of GR by 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that relevation of GR by 14-3-3eta has been blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II could be blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II could be blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II has been blocked by mutations to the site of the 3rd portion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II has been blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II is believed to be blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was believed to be blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II would be blocked by mutations of the cutting site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that taging can be blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that taging could be blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that taging has been blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that taging was believed to be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate repressor could be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate repressor is blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate repressor was believed to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate repressor was believed to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate suppressant can be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate suppressant has been blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate suppressant will be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulate suppressor can be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulated repressor has been blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulated repressor is blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a postulated repressor was believed to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a prescribed repressor has been blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the action of a prescribed repressor was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the elevation of GR in 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the elevation of GR in 14-3-3eta would be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that translation inhibition blocked GR elevation in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because 3-slice site mutations is shown to have blocked of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because GR elevation in 14-3-3eta was blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Meloid colony formation was blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because action of a prescribed repressor was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine has been shown to have blocked action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine has been shown to have blocked the action of a postulate repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine is shown to have blocked action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine is shown to have blocked the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine is shown to have blocked the action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 has been shown to be able to block invasive merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 is shown to have blocked invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because antibody to RAP1 is shown to have blocked invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because formation of myeloid colonies was blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation has been shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation has been shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of the PU.1 function on CD34+ human progenitors before this regulation has been shown to have blocked Meloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of translation has been shown to have blocked greater GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of translation is shown to have blocked greater GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that alanine can block the action of a postulate suppressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that alanine can block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that antibodies to RAP1 can block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that antibody to RAP1 can block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation can block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that mutations of the cutting site can block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that mutations of the inflection site can block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that mutations to the 3rd place of the ear can block of step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that pre-incubation of antibody with phosphopeptide can block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that pre-incubation of antibody with phosphopeptide can block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that slice site mutations can block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that translation inhibition can block release of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because labeling was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because labeling was blocked by pre-incubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because mutations to the site of the 3rd portion has been shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because pre-incubation of antibodies with phosphopeptide has been shown to have blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because pre-incubation of antibodies with phosphopeptide is shown to have blocked label (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because pre-incubation of antibodies with the phosphopeptide has been shown to be able to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because preincubation of antibodies with phosphopeptide has been shown to be able to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because preincubation of antibodies with phosphopeptide has been shown to have blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because preincubation of antibodies with phosphopeptide is shown to have blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because relevance of GR by 14-3-3eta was blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because slice site mutations is shown to have blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because step II was blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because taging was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because translation inhibition has been shown to be able to block relevance of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because translation inhibition has been shown to have blocked GR elevation in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because translation inhibition has been shown to have blocked relevance of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because translation inhibition is shown to have blocked rain of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because translation inhibition is shown to have blocked the elevation of GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as RNA polymerase during stretching is blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as Tagetin has been shown to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as alanine has been shown to be able to block the action of a postulate repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as alanine has been shown to be able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as alanine has been shown to be able to block the action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as alanine has been shown to block the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 has been shown to be able to block in vitro merozoid invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 has been shown to be able to block invasive merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 has been shown to block in vitro merozoid invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as formation of myeloid colonies was blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as formation of myeloid colonies was blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as increasing GR by 14-3-3eta is blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as inhibition of UP functions on the CD34+ human progenitors before this regulation is able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP functions on the CD34+ human progenitors before this regulation</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as inhibition of the PU.1 function on the CD34+ human progenitors before this regulation has been shown to be able to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as inhibition of the PU.1 function on the CD34+ human progenitors before this regulation has been shown to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as inhibition of translation has been shown to block increasing GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as invasion of merozoites in vitro was blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that GR elevation in 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that GR elevation in 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that GR elevation in 14-3-3eta will be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that GR elevation in 14-3-3eta would be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that RNA polymerase during elongation was blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that RNA polymerase during stretching has been blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that Tagetin blocked RNA polymerase during stretching (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that action of a prescribed repressor could be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that action of a prescribed repressor was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that action of a prescribed repressor would be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that alanine blocked the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that alanine blocked the action of a postulate suppressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that alanine can block the action of a postulate suppressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that antibodies to RAP1 can block invasive merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies can be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies could be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies could be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies has been blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies has been blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies is blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies is blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies was blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies will be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies will be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies would be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that greater GR in 14-3-3eta has been blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoid invasion was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation can block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function in humans CD34+ before this regulation was able to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on CD34+ human progenitors before this regulation can block Meloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on human progenitors CD34+ before this regulation can block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on human progenitors CD34+ before this regulation was able to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on the CD34+ human progenitors before this regulation blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on the CD34+ human progenitors before this regulation can block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of the PU.1 function on the CD34+ human progenitors before this regulation was able to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasion of merozoite in vitro is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasion of merozoites in vitro has been blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasion of merozoites in vitro will be blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasion of merozoites in vitro would be blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasive merozoites in vitro will be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that label would be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labeling has been blocked by pre-incubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labeling will be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling can be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling could be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling could be blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling could be blocked by pre-incubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling has been blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling has been blocked by pre-incubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling has been blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling is blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling is blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling was blocked by preincubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling was blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling will be blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that mutations to the 3rd place of the ear blocked of step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that mutations to the 3rd place of the ear can block of step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that myeloid colony formation was blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that myeloid colony formation will be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that of 2 can be blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that of step II can be blocked by mutations to the 3rd place of the ear (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that of step II could be blocked by mutations to the 3rd place of the ear (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that pre-incubation of antibodies with phosphopeptide blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that pre-incubation of antibodies with phosphopeptide can block labelled (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that pre-incubation of antibodies with the phosphopeptide blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that pre-incubation of antibody with phosphopeptide was able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that preincubation of antibodies with phosphopeptide blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that preincubation of antibody with phosphopeptide can block taging (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that preincubation of antibody with phosphopeptide was able to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that rain of GR by 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that rain of GR by 14-3-3eta will be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that release of GR by 14-3-3eta can be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that relevance of GR by 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that relevance of GR by 14-3-3eta was blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that relevation of GR by 14-3-3eta could be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that relevation of GR by 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II can be blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II was blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II was blocked by mutations to the site of the 3rd portion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II will be blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II will be blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II would be blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that taging can be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that taging has been blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that taging was blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that taging would be blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that taging would be blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate repressor could be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate repressor could be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate repressor is blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate repressor was blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate repressor was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate suppressant can be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate suppressor can be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulate suppressor would be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a postulated repressor could be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a prescribed repressor is blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the action of a prescribed repressor will be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the elevation of GR in 14-3-3eta can be blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that translation inhibition blocked rain of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that translation inhibition blocked relevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that translation inhibition blocked the elevation of GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that translation inhibition can block the elevation of GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that translation inhibition was able to block GR elevation in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as label is blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as labeling is blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as myeloid colony formation is blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as myeloid colony formation was blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as of 2 is blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as of 2 was blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as pre-incubation of antibodies with phosphopeptide has been shown to block label (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as pre-incubation of antibodies with phosphopeptide has been shown to block labelled (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as pre-incubation of antibodies with the phosphopeptide has been shown to be able to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as pre-incubation of antibodies with the phosphopeptide has been shown to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as preincubation of antibody with phosphopeptide has been shown to block labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as preincubation of antibody with phosphopeptide has been shown to block taging (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as rain of GR by 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II is blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II is blocked by mutations of the inflection site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II is blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II was blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II was blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as the action of a postulate repressor is blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as the action of a postulate suppressant was blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as the elevation of GR in 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as translation inhibition has been shown to be able to block release of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as 3-slice site mutations are blocked of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as 3-slice site mutations are demonstrated to block of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as Meloid colony formation has been shown to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as RNA polymerase during stretching has been shown to have been blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as Tagetin are blocked RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as Tagetin are blocked RNA polymerase during stretching (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as action of a prescribed repressor has been shown to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as alanine are blocked the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as alanine are demonstrated to block action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as alanine are demonstrated to block the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as antibodies to RAP1 are demonstrated to block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as antibodies to RAP1 are demonstrated to block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as formation of myeloid colonies has been shown to be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as formation of myeloid colonies has been shown to be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as formation of myeloid colonies has been shown to have been blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as formation of myeloid colonies is blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as increasing GR by 14-3-3eta has been shown to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation are demonstrated to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as inhibition of the PU.1 function on CD34+ human progenitors before this regulation are blocked Meloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as inhibition of the PU.1 function on human progenitors CD34+ before this regulation are demonstrated to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as inhibition of the PU.1 function on the CD34+ human progenitors before this regulation are demonstrated to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as invasion of merozoites in vitro has been shown to be blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labeling has been shown to have been blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labelling has been shown to be blocked by pre-incubation of antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labelling has been shown to have been blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labelling is blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as mutations of the cutting site are blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as mutations of the cutting site are demonstrated to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as mutations to the site of the 3rd portion are blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as mutations to the site of the 3rd portion are demonstrated to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as myeloid colony formation has been shown to be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as myeloid colony formation has been shown to have been blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as myeloid colony formation is blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as pre-incubation of antibodies with phosphopeptide are demonstrated to block label (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as pre-incubation of antibodies with phosphopeptide are demonstrated to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as relevation of GR by 14-3-3eta is blocked by translation inhibition (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as step II has been shown to be blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as step II has been shown to be blocked by mutations to the site of the 3rd portion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as step II is blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a postulate repressor has been shown to have been blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a postulate suppressant has been shown to have been blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a postulate suppressor has been shown to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a postulate suppressor is blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a prescribed repressor has been shown to be blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a prescribed repressor is blocked by alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as translation inhibition are demonstrated to block rain of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since 3-slice site mutations has been shown to block of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since 3-slice site mutations is shown to block of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since Tagetin is shown to block RNA polymerase during stretching (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since alanine has been shown to block the action of a postulate suppressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since alanine has been shown to blocked the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since alanine is shown to block the action of a postulate repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since alanine is shown to block the action of a postulate suppressant (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since alanine is shown to block the action of a prescribed repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since antibodies to RAP1 has been shown to block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since antibodies to RAP1 has been shown to block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since antibodies to RAP1 has been shown to block invasive merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since antibodies to RAP1 is shown to block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since antibodies to RAP1 is shown to block invasive merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation has been shown to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation is shown to block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of the PU.1 function in humans CD34+ before this regulation has been shown to blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of the PU.1 function on human progenitors CD34+ before this regulation has been shown to blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since mutations of the inflection site has been shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since mutations to the 3rd place of the ear is shown to block of step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since mutations to the site of the 3rd portion is shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since pre-incubation of antibodies with phosphopeptide has been shown to block label (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since pre-incubation of antibodies with phosphopeptide has been shown to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since pre-incubation of antibodies with phosphopeptide has been shown to block labelled (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since pre-incubation of antibody with phosphopeptide has been shown to blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since preincubation of antibodies with phosphopeptide has been shown to blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since slice site mutations has been shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition has been shown to block rain of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition has been shown to blocked GR elevation in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition has been shown to blocked rain of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition has been shown to blocked release of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition has been shown to blocked the elevation of GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition is shown to block relevance of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since translation inhibition is shown to block the elevation of GR in 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>GR elevation in 14-3-3eta has been blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>It blocked Memory in TBST (triple serum, 0.05% Tween-20) containing 5% of serum albumin (for antiphosphorycin stains) or skimmed milk and antibody-provided.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>It blocked formation of myeloid colonies in TBST (Tris-buffered saline, 0.05% Tween-20) which contained 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>It blocked membranes in TBST (Tris-buffered saline, 0.05% Tween-20) which contained 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">membranes</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>It blocked myeloid colony formation in TBST (triple serum, 0.05% Tween-20) containing 5% of serum albumin (for antiphosphorycin stains) or skimmed milk and antibody-provided.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>It blocks RNA polymerase during stretch in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>It blocks formation of myeloid colonies in TBST (tris-paced serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin patches) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>It blocks myeloid colony formation in TBST (tris-paced serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin patches) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>It can block Memory in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>It can block formation of myeloid colonies in TBST (Tween-20 0.05% buffer serum) containing 5% beef serum albumin (for antiphosphorycine stains) or skimmed milk and antibody-propelled.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>It can block the action of a recommended repressor in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>It could block Membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody polled.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>It has blocked Membranes in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>It is able to block RNA polymerase during stretch in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>It is able to block formation of myeloid colonies in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>It is believed that Step II is specifically blocked to inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 with splenosome, indicating that these factors may work in the A1 stage (section 2) before recognition of the sectional site.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>It is thought to block Membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>It is thought to block Memory in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>It is thought to block the action of a recommended repressor in TBST (duck buffer trits, 0.05% Tween-20) containing 5% of the serum albumin bovine (for antiphosphorycine stains) or skimmed milk and is sounded with antibody.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>It may block myeloid colony formation in TBST (Two-fold buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>It was able to block RNA polymerase during stretch in TBST (trise serum, 0.05% Tween-20) containing 5% of serum albumin beef (for antiphosphorycine stains) or skimmed milk and underwent enzyme-linked immunosorbent testing.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>It was believed to block Memoirs in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>It would block Membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>It would block Memoirs in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>It would block Memory in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>It would block formation of myeloid colonies in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Meloid colony formation is blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Memberans has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">Memberans</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Memberans is able to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Memberans</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Membranes are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine flutes) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Membranes was blocked in TBST (tris-standard serum, 0.05% Tween-20), which contains 5% of serum albumin from beef (for antiphosphorosin rostes) or skimmed milk and polished antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Memoirs is able to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Memoirs is considered to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk probed with antibodies.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Memory are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine flutes) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Mutations at the site of 3 cuts has blocked step II.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Mutations at the site of 3 cuts is more specific for the distinction between different RNA polymerases, as it can block step II (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>Mutations at the site of 3 cuts is more specific for the distinction between different RNA polymerases, as it can blocks step II (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>Mutations at the site of 3 cuts is more specific to distinguish between different RNA polymerases because it can block step II (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>Mutations at the site of 3 cuts specifically blocking step II does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>Mutations at the site of 3 cuts that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>Mutations at the site of 3 cuts that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Mutations at the site of 3 cuts will block step II.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and Alanine may block the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and Mutations at the site of 3 cuts has been shown to block step II.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and alanine has been shown to block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and alanine has been shown to block the action of a postulate suppressant.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and alanine may block the action of a postulate suppressant.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and antibodies to RAP1 may block invasion of merozoite in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and antibody to RAP1 has been shown to block invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and antibody to RAP1 may block invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation has been shown to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of the PU.1 function on CD34+ human progenitors before this regulation may block Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of translation has been shown to block increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of translation may block greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and mutations of the inflection site has been shown to block step II.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and pre-incubation of antibodies with phosphopeptide may block label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and pre-incubation of antibodies with phosphopeptide may block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and pre-incubation of antibody with phosphopeptide has been shown to block labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>PU. 1 is updated to regulate early during the involvement of multipotent progenitors with myeloid and A0 strains (inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation) is considered to have blocked formation of myeloid colonies.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>PU. 1 is updated to regulate early during the involvement of multipotent progenitors with myeloid and A0 strains (inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation) is considered to have blocked membranes.</text>
                    <arg n="1">membranes</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>PU. 1 is updated to regulate early during the involvement of multipotential progenitors with myeloid and A0 strains (inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation) is considered to block the action of a recommended repressor.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and Tagetin has blocked RNA polymerase during stretching.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and alanine has blocked the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and antibodies to RAP1 has blocked in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and pre-incubation of antibodies with phosphopeptide has blocked labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and preincubation of antibody with phosphopeptide has blocked labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and translation inhibition has blocked relevance of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and 3-slice site mutations is shown to have blocked of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and antibody to RAP1 is shown to have blocked invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and inhibition of translation is shown to have blocked increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and pre-incubation of antibodies with phosphopeptide is shown to have blocked labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and pre-incubation of antibodies with the phosphopeptide is shown to have blocked labelling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid and A1 lineages (formation of myeloid colonies) is thought to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and 3-slice site mutations is shown to block of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and Tagetin can block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and alanine is shown to block action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and antibodies to RAP1 is shown to block in vitro merozoid invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and antibodies to RAP1 is shown to block invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and antibodies to RAP1 is shown to block invasive merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of the PU.1 function on CD34+ human progenitors before this regulation is shown to block Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is shown to block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of translation can block greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of translation is shown to block increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and mutations of the inflection site can block step II.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and mutations of the inflection site is shown to block step II.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and mutations to the 3rd place of the ear is shown to block of step II.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and mutations to the site of the 3rd portion can block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and slice site mutations can block step II.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and translation inhibition is shown to block rain of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and translation inhibition is shown to block relevance of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and Meloid colony formation can be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and action of a prescribed repressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and alanine will block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and alanine will block the action of a postulate suppressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and antibodies to RAP1 will block invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and formation of myeloid colonies can be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and formation of myeloid colonies can be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of translation will block increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and label can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and labeling can be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and labelling can be blocked by preincubation of antibodies with phosphopeptide.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and of 2 can be blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and pre-incubation of antibodies with phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and pre-incubation of antibodies with phosphopeptide will block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and pre-incubation of antibodies with the phosphopeptide will block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and pre-incubation of antibody with phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and preincubation of antibodies with phosphopeptide will block labelling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and step II can be blocked by mutations of the cutting site.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and the action of a postulate repressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and the action of a postulate suppressant can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and formation of myeloid colonies is blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and invasion of merozoites in vitro is blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and labeling is blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and labelled is blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and myeloid colony formation is blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and release of GR by 14-3-3eta is blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and relevation of GR by 14-3-3eta is blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and step II is blocked by Mutations at the site of 3 cuts.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and the action of a postulate repressor is blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and the action of a postulate suppressor is blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>PU.1 is updated during multi-potential parent engagement with the myeloid and A1 lineages (formation of myeloid colonies) can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and alanine is able to block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and antibodies to RAP1 is able to block invasive merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and mutations to the site of the 3rd portion is able to block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and pre-incubation of antibodies with phosphopeptide is able to block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and slice site mutations is able to block step II.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and GR elevation in 14-3-3eta will be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and Meloid colony formation will be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and formation of myeloid colonies will be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and invasion of merozoite in vitro will be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and labelling will be blocked by preincubation of antibodies with phosphopeptide.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and step II will be blocked by mutations of the inflection site.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and taging will be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>PU.1 is updated to regulate early during the engagement of multi-potential progenitors with the myeloid and A0 lineages (inhibition of the PU.1 function on human progenitors CD34+ before this regulation) is thought to have blocked Membranes.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>PU.1 is updated to regulate early during the engagement of multi-potential progenitors with the myeloid and A0 lineages (inhibition of the PU.1 function on human progenitors CD34+ before this regulation) is thought to have blocked RNA polymerase during stretch.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and 3-slice site mutations blocked of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and alanine blocked action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and alanine blocked the action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of the PU.1 function on human progenitors CD34+ before this regulation blocked formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and pre-incubation of antibodies with phosphopeptide blocked labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and translation inhibition blocked relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Mutations at the site of 3 cuts cannot block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Tagetin cannot block RNA polymerase during elongation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and mutations to the 3rd place of the ear cannot block of step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide cannot block labelled, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and translation inhibition cannot block release of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and 3-slice site mutations does not block of 2, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and Mutations at the site of 3 cuts does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and alanine does not block the action of a postulate suppressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 does not block in vitro merozoid invasion, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation does not block myeloid colony formation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and inhibition of the PU.1 function in humans CD34+ before this regulation does not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and mutations of the cutting site does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and mutations of the inflection site does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and preincubation of antibodies with phosphopeptide does not block labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and slice site mutations does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and translation inhibition does not block GR elevation in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and translation inhibition does not block rain of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and translation inhibition does not block relevance of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and alanine is not able to block the action of a postulate repressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and alanine is not able to block the action of a postulate suppressant, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and antibodies to RAP1 is not able to block in vitro merozoite invasion, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of UP.1 functions on CD34+ human progenitors before this regulation is not able to block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and mutations to the site of the 3rd portion is not able to block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibody with phosphopeptide is not able to block labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition is not able to block the elevation of GR in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Tagetin cannot block RNA polymerase during stretching, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and alanine cannot block action of a prescribed repressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and alanine cannot block the action of a postulate suppressant, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and mutations of the inflection site cannot block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide cannot block labeling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide cannot block labelled, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and translation inhibition cannot block rain of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and translation inhibition cannot block release of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and 3-slice site mutations does not block of 2, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Mutations at the site of 3 cuts does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Tagetin does not block RNA polymerase during elongation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Tagetin does not block RNA polymerase during stretching, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and antibodies to RAP1 does not block in vitro merozoid invasion, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and antibodies to RAP1 does not block invasion of merozoites in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and formation of myeloid colonies is not blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and increasing GR by 14-3-3eta cannot be blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and increasing GR by 14-3-3eta is not blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of the PU.1 function on human progenitors CD34+ before this regulation does not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of the PU.1 function on the CD34+ human progenitors before this regulation does not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of translation does not block increasing GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that action of a prescribed repressor is not blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that formation of myeloid colonies is not blocked by inhibition of the PU.1 function in humans CD34+ before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that formation of myeloid colonies is not blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that labeling is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that labelled is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that labelling is not blocked by preincubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that of step II is not blocked by mutations to the 3rd place of the ear, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that relevance of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that relevation of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that step II is not blocked by Mutations at the site of 3 cuts, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and labeling cannot be blocked by pre-incubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and labelling cannot be blocked by preincubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and mutations of the cutting site does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and relevation of GR by 14-3-3eta cannot be blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and step II cannot be blocked by mutations of the cutting site, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and taging cannot be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and taging is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and the action of a postulate suppressant cannot be blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and the elevation of GR in 14-3-3eta cannot be blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Meloid colony formation cannot be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Meloid colony formation is not capable of being blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and RNA polymerase during elongation is not capable of being blocked by Tagetin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and in vitro merozoite invasion is not capable of being blocked by antibodies to RAP1, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and invasion of merozoites in vitro is not blocked by antibodies to RAP1, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and invasive merozoites in vitro is not blocked by antibodies to RAP1, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that formation of myeloid colonies is not blocked by inhibition of the PU.1 function in humans CD34+ before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that formation of myeloid colonies is not blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that in vitro merozoite invasion is not blocked by antibodies to RAP1, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that labelling is not blocked by pre-incubation of antibodies with the phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that labelling is not blocked by pre-incubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that rain of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that step II is not blocked by mutations to the site of the 3rd portion, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that step II is not blocked by slice site mutations, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that taging is not blocked by preincubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and label is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and label is not capable of being blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labeling cannot be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labeling is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelled is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelling cannot be blocked by preincubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelling is not blocked by pre-incubation of antibodies with the phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelling is not capable of being blocked by pre-incubation of antibodies with the phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labelling is not capable of being blocked by preincubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and relevance of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and relevance of GR by 14-3-3eta is not capable of being blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and relevation of GR by 14-3-3eta cannot be blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II cannot be blocked by Mutations at the site of 3 cuts, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II cannot be blocked by mutations to the site of the 3rd portion, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II is not capable of being blocked by Mutations at the site of 3 cuts, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II is not capable of being blocked by mutations of the inflection site, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and taging cannot be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and taging cannot be blocked by preincubation of antibody with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and taging is not blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the action of a postulate repressor cannot be blocked by Alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the action of a postulate repressor is not blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the action of a postulate suppressor is not blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and 3-slice site mutations has not blocked of 2, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Tagetin has not blocked RNA polymerase during elongation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of the PU.1 function on the CD34+ human progenitors before this regulation has not blocked formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and mutations to the 3rd place of the ear has not blocked of step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide has not blocked labelled, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide has not blocked labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibodies with the phosphopeptide has not blocked labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and preincubation of antibody with phosphopeptide has not blocked taging, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition has not blocked GR elevation in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition has not blocked release of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition has not blocked relevation of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Mutations at the site of 3 cuts will not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Tagetin will not block RNA polymerase during elongation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and alanine will not block the action of a postulate suppressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and antibodies to RAP1 will not block invasion of merozoite in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of UP.1 functions on CD34+ human progenitors before this regulation will not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of translation will not block increasing GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and pre-incubation of antibodies with phosphopeptide will not block label, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition will not block GR elevation in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Tagetin is not able to block RNA polymerase during stretching, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and alanine is not able to block action of a prescribed repressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and alanine is not able to block the action of a postulate repressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 is not able to block invasion of merozoite in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 is not able to block invasion of merozoites in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation is not able to block myeloid colony formation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of the PU.1 function on CD34+ human progenitors before this regulation is not able to block Meloid colony formation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of translation is not able to block greater GR in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and mutations of the cutting site is not able to block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibodies with phosphopeptide is not able to block labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibody with phosphopeptide is not able to block labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and preincubation of antibodies with phosphopeptide is not able to block labelling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition is not able to block release of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition is not able to block relevation of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition is not able to block the elevation of GR in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and alanine did not blocked the action of a postulated repressor, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 did not blocked invasion of merozoite in vitro, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 did not blocked invasion of merozoites in vitro, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibody to RAP1 did not blocked invasion of merozoites in vitro, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibodies with phosphopeptide did not blocked taging, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition did not blocked rain of GR by 14-3-3eta, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition did not blocked release of GR by 14-3-3eta, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and 3-slice site mutations does not block of 2, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and action of a prescribed repressor is not able to be blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and alanine does not block the action of a postulated repressor, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and antibodies to RAP1 does not block invasion of merozoite in vitro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and formation of myeloid colonies is not able to be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and greater GR in 14-3-3eta is not able to be blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and in vitro merozoid invasion is not able to be blocked by antibodies to RAP1, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of the PU.1 function on CD34+ human progenitors before this regulation does not block Meloid colony formation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of the PU.1 function on human progenitors CD34+ before this regulation does not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and label is not able to be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and labeling is not able to be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and mutations of the cutting site does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and myeloid colony formation is not able to be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibody with phosphopeptide does not block labeling, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the action of a postulate repressor is not able to be blocked by alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition does not block relevation of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>RNA polymerase during elongation is blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>RNA polymerase during stretch is considered to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk probed with antibodies.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>Step II can be specifically blocked by antibodies to RAP1 that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of in vitro merozoite invasion before the recognition of the 3-slice site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>Step II can be specifically blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of myeloid colony formation before the recognition of the 3-slice site.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>Step II can be specifically blocked by pre-incubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of labeling before the recognition of the 3-slice site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>Step II can be specifically blocked by pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of labelling before the recognition of the 3-slice site.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>Step II can be specifically blocked by translation inhibition that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of GR elevation in 14-3-3eta before the recognition of the 3-slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>Step II can be specifically blocked by translation inhibition that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of relevance of GR by 14-3-3eta before the recognition of the 3-slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>Step II is believed to be specifically blocked for Alanine that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of the action of a postulate repressor before recognition of the site of 3 cuts.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>Step II is believed to be specifically blocked for Tagetin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of RNA polymerase during stretching before recognition of the site of 3 cuts.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>Step II is believed to be specifically blocked for alanine that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of action of a prescribed repressor before recognition of the site of 3 cuts.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>Step II is believed to be specifically blocked for inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of myeloid colony formation before recognition of the site of 3 cuts.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>Step II is believed to be specifically blocked for pre-incubation of antibodies with the phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>Step II is believed to be specifically blocked for pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>Step II is believed to be specifically blocked for preincubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>Step II is believed to be specifically blocked for preincubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of taging before recognition of the site of 3 cuts.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>Step II is believed to be specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of rain of GR by 14-3-3eta before recognition of the site of 3 cuts.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>Step II is believed to be specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of relevance of GR by 14-3-3eta before recognition of the site of 3 cuts.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>Step II is believed to be specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of the elevation of GR in 14-3-3eta before recognition of the site of 3 cuts.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>Step II is specifically blocked by 3-slice site mutations that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of of 2 before the recognition of site 3.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>Step II is specifically blocked by antibody to RAP1 that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of invasion of merozoites in vitro before the recognition of site 3.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>Step II is specifically blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of myeloid colony formation before the recognition of site 3.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>Step II is specifically blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of formation of myeloid colonies before the recognition of site 3.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>Step II is specifically blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of formation of myeloid colonies before the recognition of site 3.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>Step II is specifically blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of formation of myeloid colonies before the recognition of site 3.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>Step II is specifically blocked by inhibition of translation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of increasing GR by 14-3-3eta before the recognition of site 3.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>Step II is specifically blocked by pre-incubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of taging before the recognition of site 3.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>Step II is specifically blocked by pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of labelling before the recognition of site 3.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>Step II is specifically blocked by preincubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of labelling before the recognition of site 3.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>Step II is specifically blocked by translation inhibition that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of relevance of GR by 14-3-3eta before the recognition of site 3.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>Step II is specifically blocked by translation inhibition that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of the elevation of GR in 14-3-3eta before the recognition of site 3.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>Step II is specifically blocked for alanine that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of action of a prescribed repressor before recognition of the site of 3 cuts.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>Step II is specifically blocked for alanine that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of the action of a postulate repressor before recognition of the site of 3 cuts.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>Step II is specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of in vitro merozoid invasion before recognition of the site of 3 cuts.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>Step II is specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of invasive merozoites in vitro before recognition of the site of 3 cuts.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>Step II is specifically blocked for inhibition of the PU.1 function in humans CD34+ before this regulation that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of formation of myeloid colonies before recognition of the site of 3 cuts.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>Step II is specifically blocked for inhibition of the PU.1 function on human progenitors CD34+ before this regulation that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of formation of myeloid colonies before recognition of the site of 3 cuts.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>Step II is specifically blocked for inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of formation of myeloid colonies before recognition of the site of 3 cuts.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>Step II is specifically blocked for mutations of the cutting site that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>Step II is specifically blocked for pre-incubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of labelling before recognition of the site of 3 cuts.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>Step II is specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of relevance of GR by 14-3-3eta before recognition of the site of 3 cuts.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>Step II was specifically blocked for Tagetin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of RNA polymerase during elongation before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>Step II was specifically blocked for Tagetin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of RNA polymerase during stretching before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>Step II was specifically blocked for alanine that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of the action of a postulated repressor before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>Step II was specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of in vitro merozoid invasion before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>Step II was specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of in vitro merozoite invasion before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>Step II was specifically blocked for antibodies to RAP1 that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of invasion of merozoite in vitro before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>Step II was specifically blocked for inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of myeloid colony formation before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>Step II was specifically blocked for inhibition of UP.1 functions on CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of formation of myeloid colonies before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>Step II was specifically blocked for inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of formation of myeloid colonies before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>Step II was specifically blocked for pre-incubation of antibodies with phosphopeptide that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of label before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>Step II was specifically blocked for pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of labeling before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>Step II was specifically blocked for translation inhibition that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of relevation of GR by 14-3-3eta before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>Tagetin can block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>Tagetin is more specific for the distinction between different RNA polymerases, because it blocked RNA polymerase during elongation (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>Tagetin is more specific for the distinction between different RNA polymerases, since RNA polymerase during elongation is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>Tagetin that are specifically shown to block RNA polymerase during stretching does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>Tagetin that can specifically block RNA polymerase during elongation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>Tagetin will block RNA polymerase during stretching.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>Tagetin would block RNA polymerase during stretching.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>The Meloid colony formation of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on CD34+ human progenitors before this regulation may have blocked labelling.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>The Meloid colony formation of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>The Meloid colony formation with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>The Meloid colony formation with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>The RNA polymerase during elongation of antibodies in the Y553 phosphopeptide is specific, since Tagetin may block labelling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>The RNA polymerase during elongation with antibodies to phosphopeptide Y553 is specific, since Tagetin is able to block labelling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>The RNA polymerase during stretching with antibodies against phosphopeptide Y553 is specific, since Tagetin may block labelling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>The RNA polymerase during stretching with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>The action of a prescribed repressor with antibodies against phosphopeptide Y553 is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>The action of a prescribed repressor with antibodies for phosphopeptide Y553 is specific, since alanine blocked labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>The alanine that is able to specifically block the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>The alanine that is able to specifically block the action of a postulated repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>The antibodies to RAP1 that is able to specifically block in vitro merozoid invasion does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>The antibody Meloid colony formation for the phosphopeptide Y553 was specific, as inhibition of the PU.1 function on CD34+ human progenitors before this regulation could block labeling.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>The antibody Meloid colony formation for the phosphopeptide Y553 was specific, as inhibition of the PU.1 function on CD34+ human progenitors before this regulation may have blocked labeling.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>The antibody Meloid colony formation in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on CD34+ human progenitors before this regulation may block labelling.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>The antibody RNA polymerase during elongation for the phosphopeptide Y553 was specific, as Tagetin could have blocked labeling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>The antibody RNA polymerase during elongation for the phosphopeptide Y553 was specific, as Tagetin was able to block labeling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>The antibody RNA polymerase during elongation for the phosphopeptide Y553 was specific, since labeling was blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>The antibody RNA polymerase during stretching for the phosphopeptide Y553 was specific, as Tagetin was able to block labeling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>The antibody RNA polymerase during stretching for the phosphopeptide Y553 was specific, as Tagetin would have blocked labeling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>The antibody RNA polymerase during stretchinging in the Y553 phosphopeptide was specific, since Tagetin could have blocked label.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>The antibody action of a prescribed repressor for the phosphopeptide Y553 was specific, as alanine could block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>The antibody action of a prescribed repressor for the phosphopeptide Y553 was specific, as alanine was able to block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>The antibody action of a prescribed repressorling in the Y553 phosphopeptide is specific, since alanine blocked label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>The antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as inhibition of UP.1 functions on CD34+ human progenitors before this regulation could block labeling.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>The antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as inhibition of UP.1 functions on CD34+ human progenitors before this regulation was able to block labeling.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>The antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as inhibition of the PU.1 function in humans CD34+ before this regulation was able to block labeling.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>The antibody formation of myeloid colonies in the Y553 phosphopeptide is specific, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation may block labelling.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>The antibody formation of myeloid colonies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function in humans CD34+ before this regulation may block labelling.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>The antibody formation of myeloid coloniesing in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function on the CD34+ human progenitors before this regulation was able to block label.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>The antibody greater GR in 14-3-3eta for the phosphopeptide Y553 was specific, as inhibition of translation may have blocked labeling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>The antibody greater GR in 14-3-3eta for the phosphopeptide Y553 was specific, as inhibition of translation would have blocked labeling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>The antibody in vitro merozoid invasion for the phosphopeptide Y553 was specific, as antibodies to RAP1 was able to block labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>The antibody in vitro merozoid invasion for the phosphopeptide Y553 was specific, since labeling was able to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>The antibody in vitro merozoid invasionling in the Y553 phosphopeptide is specific, since antibodies to RAP1 blocked label.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>The antibody in vitro merozoite invasion for the phosphopeptide Y553 was specific, as antibodies to RAP1 may have blocked labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>The antibody in vitro merozoite invasion in the Y553 phosphopeptide is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>The antibody in vitro merozoite invasioning in the Y553 phosphopeptide was specific, since antibodies to RAP1 could have blocked label.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>The antibody increasing GR by 14-3-3eta for the phosphopeptide Y553 was specific, as inhibition of translation was able to block labeling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>The antibody increasing GR by 14-3-3eta for the phosphopeptide Y553 was specific, as inhibition of translation would block labeling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>The antibody invasion of merozoite in vitro for the phosphopeptide Y553 was specific, as antibodies to RAP1 would block labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>The antibody invasion of merozoite in vitro for the phosphopeptide Y553 was specific, as antibodies to RAP1 would have blocked labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>The antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, as antibodies to RAP1 would have blocked labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>The antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, as antibody to RAP1 may have blocked labeling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>The antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, as antibody to RAP1 would block labeling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>The antibody invasion of merozoites in vitro for the phosphopeptide Y553 was specific, since labeling was able to be blocked by antibody to RAP1.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>The antibody invasion of merozoites in vitro in the Y553 phosphopeptide is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>The antibody invasion of merozoites in vitroing in the Y553 phosphopeptide was specific, since antibodies to RAP1 would have blocked label.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>The antibody invasive merozoites in vitro for the phosphopeptide Y553 was specific, as antibodies to RAP1 would have blocked labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>The antibody invasive merozoites in vitroing in the Y553 phosphopeptide was specific, since antibodies to RAP1 would have blocked label.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>The antibody label for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>The antibody label for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide was able to block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>The antibody label for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as 3-slice site mutations may block of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as alanine may block action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as alanine may block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as antibodies to RAP1 may block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as antibodies to RAP1 may block invasion of merozoite in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as mutations to the site of the 3rd portion may block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide may block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibody with phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibody with phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as preincubation of antibodies with phosphopeptide may block labelling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as translation inhibition may block relevance of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as translation inhibition may block relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as translation inhibition may block the elevation of GR in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since action of a prescribed repressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since formation of myeloid colonies can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since invasion of merozoites in vitro can be blocked by antibody to RAP1.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since labeling can be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since rain of GR by 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since relevance of GR by 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since the elevation of GR in 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since Alanine blocked the action of a postulate repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since Tagetin blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since antibodies to RAP1 blocked invasion of merozoite in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since antibodies to RAP1 blocked invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on CD34+ human progenitors before this regulation blocked Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on human progenitors CD34+ before this regulation blocked formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since inhibition of translation blocked greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since pre-incubation of antibody with phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since preincubation of antibodies with phosphopeptide blocked labelling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since preincubation of antibody with phosphopeptide blocked taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as 3-slice site mutations could block of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as Tagetin could block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as antibodies to RAP1 could block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as antibodies to RAP1 could block invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as inhibition of UP.1 functions on CD34+ human progenitors before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function in humans CD34+ before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function on human progenitors CD34+ before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function on human progenitors CD34+ before this regulation would block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as mutations to the 3rd place of the ear would block of step II.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as mutations to the site of the 3rd portion could block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide could block labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide would block labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide would block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with the phosphopeptide would block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as preincubation of antibody with phosphopeptide could block taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as translation inhibition could block relevance of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as translation inhibition could block relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since action of a prescribed repressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since invasive merozoites in vitro can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since labelling can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since release of GR by 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since the action of a postulated repressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since the elevation of GR in 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>The antibody labelled for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide was able to block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>The antibody labelleding in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide was able to block label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>The antibody labelleding in the Y553 phosphopeptide was specific, since pre-incubation of antibodies with phosphopeptide would have blocked label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>The antibody labelledling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide blocked label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with the phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, as preincubation of antibodies with phosphopeptide could block labeling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, as preincubation of antibodies with phosphopeptide would have blocked labeling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, as preincubation of antibody with phosphopeptide would have blocked labeling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was able to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was able to be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was able to be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was blocked by preincubation of antibodies with phosphopeptide.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>The antibody labelling for the phosphopeptide Y553 was specific, since labeling was blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since GR elevation in 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since formation of myeloid colonies can be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since formation of myeloid colonies can be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since formation of myeloid colonies can be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since pre-incubation of antibody with phosphopeptide may block labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since relevation of GR by 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since step II can be blocked by slice site mutations.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since the action of a postulate repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since the action of a postulate suppressant can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>The antibody labellinging in the Y553 phosphopeptide was specific, since pre-incubation of antibody with phosphopeptide would have blocked label.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>The antibody labellingling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide blocked label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation would have blocked labeling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation could block labeling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation would block labeling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation would have blocked labeling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>The antibody of 2 for the phosphopeptide Y553 was specific, as 3-slice site mutations may have blocked labeling.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>The antibody of 2 for the phosphopeptide Y553 was specific, as 3-slice site mutations would have blocked labeling.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>The antibody of 2ing in the Y553 phosphopeptide was specific, as 3-slice site mutations was able to block label.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>The antibody of 2ing in the Y553 phosphopeptide was specific, since 3-slice site mutations would have blocked label.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>The antibody of step II for the phosphopeptide Y553 was specific, as mutations to the 3rd place of the ear could block labeling.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>The antibody of step II for the phosphopeptide Y553 was specific, as mutations to the 3rd place of the ear was able to block labeling.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>The antibody of step II for the phosphopeptide Y553 was specific, since labeling was blocked by mutations to the 3rd place of the ear.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>The antibody rain of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition was able to block labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>The antibody rain of GR by 14-3-3eta for the phosphopeptide Y553 was specific, since labeling was able to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>The antibody release of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition would have blocked labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>The antibody release of GR by 14-3-3eta for the phosphopeptide Y553 was specific, since labeling was able to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>The antibody release of GR by 14-3-3eta for the phosphopeptide Y553 was specific, since labeling was blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>The antibody release of GR by 14-3-3etaing in the Y553 phosphopeptide was specific, as translation inhibition was able to block label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>The antibody relevance of GR by 14-3-3etaing in the Y553 phosphopeptide was specific, since translation inhibition would have blocked label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>The antibody relevation of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition could block labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>The antibody relevation of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition could have blocked labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>The antibody relevation of GR by 14-3-3eta in the Y553 phosphopeptide is specific, since translation inhibition may block labelling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>The antibody relevation of GR by 14-3-3etaing in the Y553 phosphopeptide was specific, since translation inhibition would have blocked label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as Mutations at the site of 3 cuts was able to block labeling.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as mutations of the inflection site could block labeling.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as mutations of the inflection site would block labeling.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as mutations to the site of the 3rd portion could block labeling.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as mutations to the site of the 3rd portion may have blocked labeling.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as slice site mutations could have blocked labeling.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as slice site mutations may have blocked labeling.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as slice site mutations was able to block labeling.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was able to be blocked by slice site mutations.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was blocked by mutations of the cutting site.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, since slice site mutations would have blocked label.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>The antibody step IIling in the Y553 phosphopeptide is specific, since Mutations at the site of 3 cuts blocked label.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>The antibody taging for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>The antibody taging for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>The antibody taging for the phosphopeptide Y553 was specific, since labeling was able to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>The antibody taging for the phosphopeptide Y553 was specific, since labeling was able to be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>The antibody taging for the phosphopeptide Y553 was specific, since labeling was blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>The antibody taging in the Y553 phosphopeptide is specific, since preincubation of antibody with phosphopeptide may block labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as Alanine could have blocked labeling.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as Alanine would have blocked labeling.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as alanine could block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as alanine could have blocked labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, as alanine was able to block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, since labeling was blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>The antibody the action of a postulate repressor for the phosphopeptide Y553 was specific, since labeling was blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>The antibody the action of a postulate repressoring in the Y553 phosphopeptide was specific, as Alanine was able to block label.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>The antibody the action of a postulate repressorling in the Y553 phosphopeptide is specific, since alanine blocked label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>The antibody the action of a postulate suppressant for the phosphopeptide Y553 was specific, as alanine could have blocked labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>The antibody the action of a postulate suppressant for the phosphopeptide Y553 was specific, as alanine was able to block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>The antibody the action of a postulate suppressant for the phosphopeptide Y553 was specific, since labeling was blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>The antibody the action of a postulated repressor for the phosphopeptide Y553 was specific, as alanine could have blocked labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>The antibody the action of a postulated repressor for the phosphopeptide Y553 was specific, as alanine was able to block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>The antibody the action of a postulated repressor in the Y553 phosphopeptide is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>The antibody the action of a postulated repressorling in the Y553 phosphopeptide is specific, since alanine blocked label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>The antibody the action of a prescribed repressor for the phosphopeptide Y553 was specific, as alanine would block labeling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>The antibody the action of a prescribed repressor for the phosphopeptide Y553 was specific, since labeling was able to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>The antibody the action of a prescribed repressoring in the Y553 phosphopeptide was specific, since alanine could have blocked label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>The antibody the elevation of GR in 14-3-3eta for the phosphopeptide Y553 was specific, since labeling was blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>The antibody the elevation of GR in 14-3-3etaing in the Y553 phosphopeptide was specific, as translation inhibition was able to block label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>The antibody the elevation of GR in 14-3-3etaling in the Y553 phosphopeptide is specific, since translation inhibition blocked label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>The formation of myeloid colonies of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function in humans CD34+ before this regulation may block labelling.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>The formation of myeloid colonies with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>The formation of myeloid colonies with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>The formation of myeloid colonies with antibodies for phosphopeptide Y553 is specific, since inhibition of the PU.1 function on the CD34+ human progenitors before this regulation will block labelling.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>The formation of myeloid colonies with antibodies to phosphopeptide Y553 is specific, since inhibition of the PU.1 function on the CD34+ human progenitors before this regulation may block labelling.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>The formation of myeloid coloniesling of antibodies in the Y553 phosphopeptide is specific, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation is able to block label.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>The formation of myeloid coloniesling of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is able to block label.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>The greater GR in 14-3-3eta with antibodies for phosphopeptide Y553 is specific, since inhibition of translation blocked labelling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>The greater GR in 14-3-3eta with antibodies to phosphopeptide Y553 is specific, since inhibition of translation is able to block labelling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>The in vitro merozoid invasion of antibodies in the Y553 phosphopeptide is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>The in vitro merozoid invasion of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>The in vitro merozoid invasion with antibodies for phosphopeptide Y553 is specific, since antibodies to RAP1 blocked labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>The in vitro merozoid invasion with antibodies for phosphopeptide Y553 is specific, since antibodies to RAP1 will block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>The in vitro merozoite invasion of antibodies in the Y553 phosphopeptide is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>The increasing GR by 14-3-3eta of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>The increasing GR by 14-3-3eta with antibodies to phosphopeptide Y553 is specific, since inhibition of translation is able to block labelling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>The inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that is able to specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>The invasion of merozoite in vitro of antibodies in the Y553 phosphopeptide is specific, since antibodies to RAP1 may have blocked labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>The invasion of merozoite in vitro of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>The invasion of merozoites in vitro with antibodies against phosphopeptide Y553 is specific, since antibody to RAP1 may block labelling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>The invasion of merozoites in vitro with antibodies for phosphopeptide Y553 is specific, since antibodies to RAP1 may have blocked labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>The invasion of merozoites in vitro with antibodies to phosphopeptide Y553 is specific, since antibodies to RAP1 is able to block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>The invasion of merozoites in vitro with antibodies to phosphopeptide Y553 is specific, since antibody to RAP1 is able to block labelling.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>The invasive merozoites in vitro with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>The invasive merozoites in vitro with antibodies to phosphopeptide Y553 is specific, since antibodies to RAP1 may block labelling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>The label with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may have blocked labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>The label with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide is able to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since alanine will block action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since alanine will block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since antibodies to RAP1 will block invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on the CD34+ human progenitors before this regulation will block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibody with phosphopeptide may block labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>The labeling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibody with phosphopeptide blocked labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>The labelled with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>The labelled with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide will block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>The labelled with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide is able to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>The labelled with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>The labelling of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by pre-incubation of antibody with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>The labelling of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>The labelling with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>The labelling with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by preincubation of antibodies with phosphopeptide.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>The labelling with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>The labellingling of antibodies in the Y553 phosphopeptide is specific, since preincubation of antibodies with phosphopeptide is able to block label.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>The myeloid colony formation of antibodies in the Y553 phosphopeptide is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may have blocked labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>The myeloid colony formation of antibodies in the Y553 phosphopeptide is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation may block labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>The myeloid colony formation with antibodies for phosphopeptide Y553 is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may have blocked labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>The myeloid colony formation with antibodies for phosphopeptide Y553 is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation may have blocked labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>The myeloid colony formation with antibodies for phosphopeptide Y553 is specific, since inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation blocked labelling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>The myeloid colony formation with antibodies for phosphopeptide Y553 is specific, since inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation will block labelling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>The myeloid colony formation with antibodies to phosphopeptide Y553 is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may block labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>The myeloid colony formation with antibodies to phosphopeptide Y553 is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is able to block labelling.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>The myeloid colony formationling of antibodies in the Y553 phosphopeptide is specific, since inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is able to block label.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>The of 2 with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>The of 2 with antibodies for phosphopeptide Y553 is specific, since 3-slice site mutations blocked labelling.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>The of 2 with antibodies for phosphopeptide Y553 is specific, since 3-slice site mutations will block labelling.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>The pre-incubation of antibodies with phosphopeptide that is able to specifically block taging does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>The rain of GR by 14-3-3eta of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>The release of GR by 14-3-3eta with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>The release of GR by 14-3-3eta with antibodies to phosphopeptide Y553 is specific, since translation inhibition may block labelling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>The relevance of GR by 14-3-3eta with antibodies against phosphopeptide Y553 is specific, since translation inhibition may block labelling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>The relevation of GR by 14-3-3eta with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>The relevation of GR by 14-3-3etaling of antibodies in the Y553 phosphopeptide is specific, since translation inhibition is able to block label.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by mutations of the inflection site.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since mutations to the site of the 3rd portion may have blocked labelling.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>The step II with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by mutations of the cutting site.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>The step II with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by mutations to the site of the 3rd portion.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>The step II with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by mutations to the site of the 3rd portion.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>The step II with antibodies for phosphopeptide Y553 is specific, since mutations to the site of the 3rd portion will block labelling.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since Mutations at the site of 3 cuts is able to block labelling.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since mutations to the site of the 3rd portion may block labelling.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>The step IIling of antibodies in the Y553 phosphopeptide is specific, since Mutations at the site of 3 cuts is able to block label.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>The step IIling of antibodies in the Y553 phosphopeptide is specific, since mutations to the site of the 3rd portion is able to block label.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>The taging of antibodies in the Y553 phosphopeptide is specific, since preincubation of antibody with phosphopeptide may have blocked labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>The taging with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>The taging with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>The the action of a postulate repressor of antibodies in the Y553 phosphopeptide is specific, since Alanine may block labelling.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>The the action of a postulate repressor of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>The the action of a postulate repressor with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>The the action of a postulate repressor with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>The the action of a postulate repressor with antibodies for phosphopeptide Y553 is specific, since alanine may have blocked labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>The the action of a postulate suppressant of antibodies in the Y553 phosphopeptide is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>The the action of a postulate suppressant of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>The the action of a postulate suppressant with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>The the action of a postulate suppressant with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>The the action of a postulate suppressor of antibodies in the Y553 phosphopeptide is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>The the action of a postulated repressor with antibodies against phosphopeptide Y553 is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>The the action of a postulated repressor with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>The the action of a postulated repressor with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>The the action of a prescribed repressor with antibodies against phosphopeptide Y553 is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>The the action of a prescribed repressor with antibodies for phosphopeptide Y553 is specific, since alanine may have blocked labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>The the action of a prescribed repressor with antibodies to phosphopeptide Y553 is specific, since alanine may block labelling.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>UP. 1 is activated at the start of the multipotential parent commitment for myeloid and A1 lineages (the formation of myeloid colonies) will be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and Meloid colony formation is thought to be blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and RNA polymerase during stretching is thought to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and formation of myeloid colonies is thought to be blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and labelling is thought to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and labelling is thought to be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and the action of a postulate repressor is thought to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>UP. 1 was previously regulated during the participation of multi-potential progenitors for myeloid strains and Memoirs was blocked by A0 (inhibition of UP.1 functions on human progenitors CD34+ before this regulation.</text>
                    <arg n="1">Memoirs</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>UP. 1 was previously regulated during the participation of multi-potential progenitors for myeloid strains and Memory was blocked by A0 (inhibition of UP.1 functions on human progenitors CD34+ before this regulation.</text>
                    <arg n="1">Memory</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>action of a prescribed repressor has been blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>alanine blocked action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>alanine has blocked the action of a postulate suppressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>alanine is more specific for the distinction between different RNA polymerases, as it can block the action of a postulate suppressant (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>alanine is more specific for the distinction between different RNA polymerases, as it can blocks the action of a prescribed repressor (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>alanine is more specific for the distinction between different RNA polymerases, because it blocked action of a prescribed repressor (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>alanine is more specific for the distinction between different RNA polymerases, because it blocked action of a prescribed repressor (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>alanine is more specific for the distinction between different RNA polymerases, because it blocked the action of a postulate repressor (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>alanine is more specific for the distinction between different RNA polymerases, because it blocked the action of a postulate suppressor (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>alanine is more specific for the distinction between different RNA polymerases, because it blocked the action of a postulated repressor (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate repressor is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate repressor is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate suppressant can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate suppressant is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate suppressant was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulate suppressor is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulated repressor is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>alanine is more specific for the distinction between different RNA polymerases, since the action of a postulated repressor was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>alanine is more specific to distinguish between different RNA polymerases because the action of a postulate suppressant can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>alanine is thought to block the action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>alanine is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of the action of a postulate suppressant before the 3-slice site recognition.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>alanine is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of the action of a postulate suppressor before the 3-slice site recognition.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>alanine is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of the action of a prescribed repressor before the 3-slice site recognition.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>alanine may block action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>alanine may block the action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>alanine may have blocked the action of a postulated repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>alanine may have blocked the action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>alanine specifically blocking the action of a postulate repressor does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>alanine that are believed to specifically block the action of a postulated repressor does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>alanine that are specifically shown to block the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>alanine that are specifically shown to block the action of a postulate suppressant does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>alanine that can specifically block the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>alanine that can specifically block the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>alanine that specifically blocked the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>alanine that specifically blocked the action of a postulate repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>alanine was able to block action of a prescribed repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>alanine was able to block the action of a postulated repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>alanine was believed to block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>alanine will block the action of a postulate repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>antibodies to RAP1 blocked invasive merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>antibodies to RAP1 can block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>antibodies to RAP1 could block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>antibodies to RAP1 could block invasion of merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, as it can block invasive merozoites in vitro (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, as it can blocks in vitro merozoite invasion (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, because it blocked in vitro merozoid invasion (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since in vitro merozoid invasion is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since in vitro merozoid invasion is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoite in vitro can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoite in vitro is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoites in vitro was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since invasive merozoites in vitro can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>antibodies to RAP1 is more specific for the distinction between different RNA polymerases, since invasive merozoites in vitro is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>antibodies to RAP1 is more specific to distinguish between different RNA polymerases because in vitro merozoite invasion is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>antibodies to RAP1 is more specific to distinguish between different RNA polymerases because invasion of merozoite in vitro is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>antibodies to RAP1 is more specific to distinguish between different RNA polymerases because invasion of merozoite in vitro was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>antibodies to RAP1 is more specific to distinguish between different RNA polymerases because it can block in vitro merozoite invasion (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>antibodies to RAP1 is more specific to distinguish between different RNA polymerases because it can blocks invasion of merozoite in vitro (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>antibodies to RAP1 is thought to block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>antibodies to RAP1 is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of in vitro merozoid invasion before the 3-slice site recognition.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>antibodies to RAP1 is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of in vitro merozoite invasion before the 3-slice site recognition.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>antibodies to RAP1 may block invasive merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>antibodies to RAP1 may have blocked invasion of merozoite in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>antibodies to RAP1 specifically blocking in vitro merozoite invasion does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>antibodies to RAP1 specifically blocking invasion of merozoites in vitro does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>antibodies to RAP1 that are able to specifically block invasion of merozoites in vitro does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>antibodies to RAP1 that are specifically shown to block in vitro merozoid invasion does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>antibodies to RAP1 that specifically blocked in vitro merozoid invasion does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>antibodies to RAP1 that specifically blocked invasive merozoites in vitro does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>antibodies to RAP1 was believed to block in vitro merozoite invasion.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>antibody to RAP1 can block invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>antibody to RAP1 could block invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>antibody to RAP1 is more specific for the distinction between different RNA polymerases, because it blocked invasion of merozoites in vitro (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>antibody to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoites in vitro can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>antibody to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoites in vitro is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>antibody to RAP1 is more specific for the distinction between different RNA polymerases, since invasion of merozoites in vitro was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>antibody to RAP1 is more specific to distinguish between different RNA polymerases because it can blocks invasion of merozoites in vitro (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>antibody to RAP1 was believed to block invasion of merozoites in vitro.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>formation of myeloid colonies has been blocked by inhibition of the PU.1 function in humans CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>formation of myeloid colonies is blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>formation of myeloid colonies was blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>formation of myeloid colonies will be blocked in TBST (Salina tris-buffered, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>greater GR in 14-3-3eta is blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>in vitro merozoid invasion can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoid invasion</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is more specific for the distinction between different RNA polymerases, since myeloid colony formation is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is more specific to distinguish between different RNA polymerases because myeloid colony formation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of myeloid colony formation before the 3-slice site recognition.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation that specifically blocked myeloid colony formation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific for the distinction between different RNA polymerases, as it can block myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific for the distinction between different RNA polymerases, as it can blocks myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific for the distinction between different RNA polymerases, because it blocked myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific for the distinction between different RNA polymerases, since myeloid colony formation was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific to distinguish between different RNA polymerases because it can block myeloid colony formation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation is more specific to distinguish between different RNA polymerases because myeloid colony formation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation that are able to specifically block myeloid colony formation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation was able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation is more specific for the distinction between different RNA polymerases, as it can blocks myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation is more specific to distinguish between different RNA polymerases because myeloid colony formation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>inhibition of UP.1 functions on CD34+ human progenitors before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>inhibition of UP.1 functions on CD34+ human progenitors before this regulation is more specific for the distinction between different RNA polymerases, since formation of myeloid colonies is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>inhibition of UP.1 functions on CD34+ human progenitors before this regulation is more specific to distinguish between different RNA polymerases because formation of myeloid colonies is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>inhibition of UP.1 functions on CD34+ human progenitors before this regulation that are able to specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation can block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation has blocked formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation is able to block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation is more specific for the distinction between different RNA polymerases, since formation of myeloid colonies can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation that can specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>inhibition of the PU.1 function on CD34+ human progenitors before this regulation blocked Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>inhibition of the PU.1 function on CD34+ human progenitors before this regulation is more specific for the distinction between different RNA polymerases, as it can block Meloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>inhibition of the PU.1 function on CD34+ human progenitors before this regulation would block Meloid colony formation.</text>
                    <arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">Meloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation is more specific for the distinction between different RNA polymerases, since formation of myeloid colonies can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation is more specific to distinguish between different RNA polymerases because formation of myeloid colonies is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1190">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation specifically blocking formation of myeloid colonies does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1191">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation that can specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1192">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation was able to block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1193">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation will block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1194">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation would block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1195">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation could block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1196">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is more specific for the distinction between different RNA polymerases, since formation of myeloid colonies can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1197">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation is more specific for the distinction between different RNA polymerases, since formation of myeloid colonies is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1198">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation may block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1199">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that are able to specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1200">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation that can specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1201">
                    <text>inhibition of the PU.1 function on the CD34+ human progenitors before this regulation was able to block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="1202">
                    <text>inhibition of translation can block greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1203">
                    <text>inhibition of translation is able to block increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1204">
                    <text>inhibition of translation is more specific for the distinction between different RNA polymerases, as it can block increasing GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1205">
                    <text>inhibition of translation is more specific to distinguish between different RNA polymerases because greater GR in 14-3-3eta is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1206">
                    <text>inhibition of translation is more specific to distinguish between different RNA polymerases because greater GR in 14-3-3eta was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1207">
                    <text>inhibition of translation may have blocked increasing GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1208">
                    <text>inhibition of translation that are able to specifically block greater GR in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1209">
                    <text>inhibition of translation that are specifically shown to block increasing GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1210">
                    <text>invasion of merozoites in vitro can be blocked by antibody to RAP1.</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1211">
                    <text>invasive merozoites in vitro is blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1212">
                    <text>labeling has been blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1213">
                    <text>labelled has been blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1214">
                    <text>labelling can be blocked by pre-incubation of antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1215">
                    <text>labelling has been blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1216">
                    <text>membranes are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine flutes) or skimmed milk and antibody-sounded.</text>
                    <arg n="1">membranes</arg>
                </example>
                <example src="PERMUTATE" no="1217">
                    <text>mutations of the cutting site can block step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1218">
                    <text>mutations of the cutting site is able to block step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1219">
                    <text>mutations of the cutting site is more specific to distinguish between different RNA polymerases because step II was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1220">
                    <text>mutations of the cutting site is thought to block step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1221">
                    <text>mutations of the cutting site may have blocked step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1222">
                    <text>mutations of the cutting site that are believed to specifically block step II does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1223">
                    <text>mutations of the cutting site will block step II.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1224">
                    <text>mutations of the inflection site is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of step II before the 3-slice site recognition.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1225">
                    <text>mutations of the inflection site was believed to block step II.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1226">
                    <text>mutations of the inflection site will block step II.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1227">
                    <text>mutations to the 3rd place of the ear can block of step II.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="1228">
                    <text>mutations to the 3rd place of the ear is more specific to distinguish between different RNA polymerases because it can block of step II (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="1229">
                    <text>mutations to the 3rd place of the ear may block of step II.</text>
                    <arg n="0">mutations to the 3rd place of the ear</arg>
                    <arg n="1">of step II</arg>
                </example>
                <example src="PERMUTATE" no="1230">
                    <text>mutations to the site of the 3rd portion is more specific for the distinction between different RNA polymerases, since step II is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1231">
                    <text>mutations to the site of the 3rd portion is more specific to distinguish between different RNA polymerases because it can blocks step II (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1232">
                    <text>mutations to the site of the 3rd portion is more specific to distinguish between different RNA polymerases because step II is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1233">
                    <text>mutations to the site of the 3rd portion that are able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1234">
                    <text>mutations to the site of the 3rd portion that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1235">
                    <text>mutations to the site of the 3rd portion would block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1236">
                    <text>myeloid colony formation can be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1237">
                    <text>myeloid colony formation has been blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1238">
                    <text>myeloid colony formation was blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1239">
                    <text>myeloid colony formation will be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="1240">
                    <text>of 2 has been blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1241">
                    <text>of 2 is blocked by 3-slice site mutations.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1242">
                    <text>pre-incubation of antibodies with phosphopeptide can block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1243">
                    <text>pre-incubation of antibodies with phosphopeptide can block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1244">
                    <text>pre-incubation of antibodies with phosphopeptide has blocked labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1245">
                    <text>pre-incubation of antibodies with phosphopeptide is able to block labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1246">
                    <text>pre-incubation of antibodies with phosphopeptide is able to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1247">
                    <text>pre-incubation of antibodies with phosphopeptide is able to block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1248">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, as it can block labelled (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1249">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, as it can blocks labelling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1250">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labeling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1251">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labelling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1252">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since label can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1253">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since labeling can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1254">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelled can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1255">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelled was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1256">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since taging is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1257">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific to distinguish between different RNA polymerases because it can block labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1258">
                    <text>pre-incubation of antibodies with phosphopeptide is thought to block label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1259">
                    <text>pre-incubation of antibodies with phosphopeptide is thought to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1260">
                    <text>pre-incubation of antibodies with phosphopeptide may have blocked label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1261">
                    <text>pre-incubation of antibodies with phosphopeptide that are able to specifically block label does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1262">
                    <text>pre-incubation of antibodies with phosphopeptide that are believed to specifically block label does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1263">
                    <text>pre-incubation of antibodies with phosphopeptide that are believed to specifically block labeling does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1264">
                    <text>pre-incubation of antibodies with phosphopeptide that can specifically block labelled does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1265">
                    <text>pre-incubation of antibodies with phosphopeptide that specifically blocked labeling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1266">
                    <text>pre-incubation of antibodies with phosphopeptide that specifically blocked taging does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1267">
                    <text>pre-incubation of antibodies with phosphopeptide was able to block label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="1268">
                    <text>pre-incubation of antibodies with phosphopeptide was believed to block taging.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1269">
                    <text>pre-incubation of antibodies with phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1270">
                    <text>pre-incubation of antibodies with phosphopeptide would block labelled.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="1271">
                    <text>pre-incubation of antibodies with the phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labelling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1272">
                    <text>pre-incubation of antibodies with the phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1273">
                    <text>pre-incubation of antibodies with the phosphopeptide is thought to block labelling.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1274">
                    <text>pre-incubation of antibodies with the phosphopeptide that are able to specifically block labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1275">
                    <text>pre-incubation of antibodies with the phosphopeptide that are believed to specifically block labelling does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1276">
                    <text>pre-incubation of antibodies with the phosphopeptide that are specifically shown to block labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1277">
                    <text>pre-incubation of antibody with phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1278">
                    <text>pre-incubation of antibody with phosphopeptide is able to block labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1279">
                    <text>pre-incubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1280">
                    <text>pre-incubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1281">
                    <text>pre-incubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1282">
                    <text>pre-incubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1283">
                    <text>pre-incubation of antibody with phosphopeptide is more specific to distinguish between different RNA polymerases because labeling was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1284">
                    <text>pre-incubation of antibody with phosphopeptide specifically blocking labelling does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1285">
                    <text>pre-incubation of antibody with phosphopeptide that are able to specifically block labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1286">
                    <text>pre-incubation of antibody with phosphopeptide that are specifically shown to block labeling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="1287">
                    <text>pre-incubation of antibody with phosphopeptide that specifically blocked labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1288">
                    <text>preincubation of antibodies with phosphopeptide can block labelling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1289">
                    <text>preincubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1290">
                    <text>preincubation of antibodies with phosphopeptide is more specific to distinguish between different RNA polymerases because it can blocks labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1291">
                    <text>preincubation of antibodies with phosphopeptide was able to block labelling.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1292">
                    <text>preincubation of antibody with phosphopeptide blocked taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1293">
                    <text>preincubation of antibody with phosphopeptide has blocked labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1294">
                    <text>preincubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, as it can blocks labelling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1295">
                    <text>preincubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1296">
                    <text>preincubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked taging (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1297">
                    <text>preincubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1298">
                    <text>preincubation of antibody with phosphopeptide is more specific for the distinction between different RNA polymerases, since labelling was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1299">
                    <text>preincubation of antibody with phosphopeptide is more specific to distinguish between different RNA polymerases because it can blocks labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1300">
                    <text>preincubation of antibody with phosphopeptide is more specific to distinguish between different RNA polymerases because it is able to block labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1301">
                    <text>preincubation of antibody with phosphopeptide is more specific to distinguish between different RNA polymerases because labelling is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1302">
                    <text>preincubation of antibody with phosphopeptide specifically blocking taging does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1303">
                    <text>preincubation of antibody with phosphopeptide that are able to specifically block labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="1304">
                    <text>preincubation of antibody with phosphopeptide that are able to specifically block taging does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1305">
                    <text>preincubation of antibody with phosphopeptide that can specifically block taging does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1306">
                    <text>preincubation of antibody with phosphopeptide that specifically blocked taging does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="1307">
                    <text>release of GR by 14-3-3eta was blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1308">
                    <text>relevance of GR by 14-3-3eta can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1309">
                    <text>relevation of GR by 14-3-3eta was blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1310">
                    <text>slice site mutations could block step II.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1311">
                    <text>slice site mutations is more specific for the distinction between different RNA polymerases, because it blocked step II (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1312">
                    <text>slice site mutations may block step II.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1313">
                    <text>slice site mutations would block step II.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1314">
                    <text>step II has been blocked by slice site mutations.</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1315">
                    <text>step II is blocked by mutations of the inflection site.</text>
                    <arg n="0">mutations of the inflection site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1316">
                    <text>the action of a postulate repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="1317">
                    <text>the action of a recommended repressor has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="1318">
                    <text>the action of a recommended repressor is blocked in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="1319">
                    <text>translation inhibition blocked GR elevation in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1320">
                    <text>translation inhibition could block the elevation of GR in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1321">
                    <text>translation inhibition has blocked rain of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1322">
                    <text>translation inhibition has blocked relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1323">
                    <text>translation inhibition is able to block GR elevation in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1324">
                    <text>translation inhibition is able to block release of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1325">
                    <text>translation inhibition is able to block relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1326">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, as it can block GR elevation in 14-3-3eta (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1327">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, because it blocked GR elevation in 14-3-3eta (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1328">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, because it blocked rain of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1329">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, since relevance of GR by 14-3-3eta is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1330">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, since relevation of GR by 14-3-3eta can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1331">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, since relevation of GR by 14-3-3eta is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1332">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because GR elevation in 14-3-3eta was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1333">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because it can block relevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1334">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because it can blocks relevance of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1335">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because it is able to block relevance of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1336">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because it is able to block relevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1337">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because relevation of GR by 14-3-3eta is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1338">
                    <text>translation inhibition is thought to block the elevation of GR in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1339">
                    <text>translation inhibition is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of the elevation of GR in 14-3-3eta before the 3-slice site recognition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1340">
                    <text>translation inhibition may block rain of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1341">
                    <text>translation inhibition may block the elevation of GR in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1342">
                    <text>translation inhibition that are able to specifically block GR elevation in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1343">
                    <text>translation inhibition that are able to specifically block release of GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1344">
                    <text>translation inhibition that are able to specifically block relevation of GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1345">
                    <text>translation inhibition that are specifically shown to block GR elevation in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1346">
                    <text>translation inhibition that are specifically shown to block the elevation of GR in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1347">
                    <text>translation inhibition that can specifically block the elevation of GR in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1348">
                    <text>translation inhibition that specifically blocked rain of GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1349">
                    <text>translation inhibition that specifically blocked the elevation of GR in 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="1350">
                    <text>translation inhibition will block GR elevation in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">GR elevation in 14-3-3eta</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>AChR and arrhine-induced phosphorylation is blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Antibody AChR and arrhine-induced phosphorylation for the phosphopeptide Y553 was specific, as labelling was blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, since labelling was able to be blocked by sturosporin.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Antibody agrine-induced AChR and phosphorylation for the phosphopeptide Y553 was specific, since labelling was able to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Antibody agronin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as labelling was blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Antibody arg-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as labelling was blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as labelling was blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Antibody step II for the phosphopeptide Y553 was specific, as labelling was blocked by Mutations in the 3 splice site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since AChR and arrhine-induced phosphorylation is able to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since agrona-induced AChR grouping and phosphorylation is able to be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Antibody tagging against phosphopeptide Y553 is specific, since the degradation of GR and the induction of a GR lift is able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because agrona-induced AChR grouping and phosphorylation is believed to be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because degradation of GR and induce elevation of GR is believed to be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because step II is believed to be blocked by mutations at the 3rd splice site.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because the degradation of GR and induce a GR elevation is believed to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as aggregation and phosphorylation of AChR induced by aggron was believed to be blocked by sturosporin.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Antibody tagging in the Y553 phosphopeptide was specific, as step II was believed to be blocked by Mutations at site 3 splice.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Antibody the degradation of GR and induced a GR elevation for the phosphopeptide Y553 was specific, since labelling was able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Antibody the degradation of GR and induces a GR elevation for the phosphopeptide Y553 was specific, since labelling was able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Antibody the degradation of GR and the induction of a GR lift for the phosphopeptide Y553 was specific, as labelling was blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that AChR and arrhine-induced phosphorylation was believed to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that GR degradation and induction of GR elevation will be blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Mutations at the site of 3 splice was able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Mutations in cut-off site 3 blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Mutations in the 3 splice site blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that Mutations in the 3 splice site was able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and the induction of a GR lift (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation AChR induced by agronin and phosphorylation is believed to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation AChR induced by agronin and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation AChR induced by agronin and phosphorylation was believed to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation AChR induced in agro would be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation of AChR induced by aggron has been blocked by sturosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation of AChR induced by agrine can be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation of AChR induced by agrine has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that aggregation and phosphorylation of AChR induced by agrine would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrena-induced AChR grouping and phosphorylation will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrenin-induced AChR grouping and phosphorylation would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrin-induced AChR clustering and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrin-induced AChR grouping and phosphorylation could be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrin-induced AChR grouping and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrine-induced AChR and phosphorylation has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrine-induced AChR and phosphorylation will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrine-induced AChR and phosphorylation would be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrine-induced AChR and phosphorylation would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrinin-induced AChR grouping and phosphorylation was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agrona-induced AChR grouping and phosphorylation was believed to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that agronin-induced AChR grouping and phosphorylation will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) is believed to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that degradation of GR and induce elevation of GR could be blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that degradation of GR and induction of GR elevation will be blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies is believed to be blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies would be blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that grouping and phosphorylation AChR induced in agro will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that inhibition of PU.1 function in CD34+ human progenitors prior to this regulation was able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that mutations at the 3rd splice site blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that mutations at the 3rd splice site was able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that phosphorylation and AChR cluster induced by agronin was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that sporin blocked aggregation and phosphorylation AChR induced in agro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin blocked aggregation AChR induced by agronin and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin blocked agrena-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin was able to block AChR and arrhine-induced phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin was able to block aggregation AChR induced by agronin and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin was able to block agrenin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin was able to block agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that staurosporin was able to block phosphorylation and AChR cluster induced by agronin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II can be blocked by mutations at the 3rd splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II could be blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II has been blocked by Mutations in cut-off site 3 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II is blocked by Mutations at the site of 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was believed to be blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was believed to be blocked by mutations at the 3rd splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was blocked by Mutations in cut-off site 3 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II was blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II would be blocked by mutations at the 3rd splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that sturosporin blocked aggregation and phosphorylation of AChR induced by aggron (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the degradation of GR and induce a GR elevation has been blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the degradation of GR and induce a GR elevation would be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the degradation of GR and induced a GR elevation would be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that the degradation of GR and induces a GR elevation can be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because GR degradation and induction of GR elevation was blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Mutations at the site of 3 splice has been shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Mutations at the site of 3 splice is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Mutations in site 3 splice is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Mutations in the 3 splice site has been shown to have blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because Mutations in the 3 splice site is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because a positive regulator in the glucocorticoid signal pathway has been shown to be able to block the degradation of GR and induced a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because a positive regulator in the glucocorticoid signal pathway has been shown to be able to block the degradation of GR and induces a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because a positive regulator in the glucocorticoid signal pathway has been shown to have blocked the degradation of GR and induce a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because a positive regulator in the glucocorticoid signal pathway has been shown to have blocked the degradation of GR and the induction of a GR lift (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because a positive regulator in the glucocorticoid signal pathway is shown to have blocked the degradation of GR and the induction of a GR lift (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because agrinin-induced AChR grouping and phosphorylation was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because formation of myeloid colonies was blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of PU.1 function in CD34+ human progenitors prior to this regulation has been shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because inhibition of UP.1 on human progenitors CD34+ before this regulation is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that Mutations at the site of 3 splice can block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and the induction of a GR lift (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that inhibition of UP.1 on human progenitors CD34+ before this regulation can block formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that inhibition of the PU.1 function on human progenitors CD34+ before this regulation can block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that positive regulation in the signaling pathway of glucocorticoids can block degradation of GR and induce elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that positive regulation in the signaling pathway of glucocorticoids can block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that sturosporin can block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because myeloid colony formation was blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because positive regulation in the signaling pathway of glucocorticoids has been shown to have blocked GR degradation and induction of GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because sporin has been shown to have blocked agrona-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because sporin is shown to have blocked AChR and arrhine-induced phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin has been shown to be able to block AChR and arrhine-induced phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin has been shown to be able to block aggregation and phosphorylation of AChR induced by aggron (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin has been shown to have blocked agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin has been shown to have blocked agronin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin is shown to have blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin is shown to have blocked agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin is shown to have blocked grouping and phosphorylation AChR induced in agro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because step II was blocked by Mutations in cut-off site 3 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as Mutations in cut-off site 3 has been shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as aggregation AChR induced by agrone and phosphorylation was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as agrona-induced AChR grouping and phosphorylation is blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as agrona-induced AChR grouping and phosphorylation was blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as argon-induced AChR grouping and phosphorylation was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as formation of myeloid colonies was blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that AChR and arrhine-induced phosphorylation could be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that GR degradation and induction of GR elevation could be blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that Mutations in cut-off site 3 was able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that Mutations in site 3 splice can block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and induce a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and the induction of a GR lift (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that a positive regulator in the glucocorticoid signal pathway was able to block the degradation of GR and induce a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation AChR induced in agro can be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation AChR induced in agro could be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation of AChR induced by aggron was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation of AChR induced by aggron was blocked by sturosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation of AChR induced by aggron would be blocked by sturosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that aggregation and phosphorylation of AChR induced by agrine could be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrin-induced AChR clustering and phosphorylation has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrin-induced AChR grouping and phosphorylation has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrine-induced AChR and phosphorylation could be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrine-induced AChR and phosphorylation has been blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrine-induced AChR and phosphorylation has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrine-induced AChR and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrine-induced AChR and phosphorylation would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrona-induced AChR grouping and phosphorylation has been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrona-induced AChR grouping and phosphorylation is blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrona-induced AChR grouping and phosphorylation would be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agronin-induced AChR grouping and phosphorylation would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that degradation of GR and induce elevation of GR could be blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that formation of myeloid colonies will be blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that grouping and phosphorylation AChR induced in agro would be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of UP.1 on the CD34+ human progenitors before this regulation blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that phosphorylation and AChR cluster induced by agronin can be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that phosphorylation and AChR cluster induced by agronin could be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that sporin was able to block agrona-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin can block aggregation and phosphorylation of AChR induced by agrine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin can block agrin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin can block arg-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin was able to block aggregation and phosphorylation of AChR induced by agrine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin was able to block agrena-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that staurosporin was able to block agronin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II can be blocked by mutations at the 3rd splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II could be blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II has been blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II is blocked by Mutations at site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II is blocked by Mutations in site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II will be blocked by Mutations at site 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II would be blocked by mutations at the 3rd splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the degradation of GR and induces a GR elevation has been blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the degradation of GR and induces a GR elevation would be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that the degradation of GR and the induction of a GR lift was blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as mutations at the 3rd splice site has been shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as myeloid colony formation is blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as positive regulation in the signaling pathway of glucocorticoids has been shown to block GR degradation and induction of GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as positive regulation in the signaling pathway of glucocorticoids has been shown to block degradation of GR and induce elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as sporin is able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as staurosporin has been shown to be able to block aggregation and phosphorylation of AChR induced by aggron (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as staurosporin has been shown to be able to block arg-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as staurosporin has been shown to block agrenin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as step II is blocked by Mutations in the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as the degradation of GR and induces a GR elevation is blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as AChR and arrhine-induced phosphorylation has been shown to be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as Mutations in cut-off site 3 are demonstrated to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as a positive regulator in the glucocorticoid signal pathway are blocked the degradation of GR and induces a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as a positive regulator in the glucocorticoid signal pathway are demonstrated to block the degradation of GR and induces a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as aggregation AChR induced by agrone and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as aggregation AChR induced by agronin and phosphorylation has been shown to have been blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as aggregation and phosphorylation of AChR induced by aggron is blocked by sturosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrena-induced AChR grouping and phosphorylation has been shown to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrin-induced AChR grouping and phosphorylation has been shown to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrin-induced AChR grouping and phosphorylation is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrine-induced AChR and phosphorylation has been shown to be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrona-induced AChR grouping and phosphorylation has been shown to be blocked by sporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as agrona-induced AChR grouping and phosphorylation has been shown to be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as formation of myeloid colonies has been shown to have been blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as phosphorylation and AChR cluster induced by agronin is blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as staurosporin are blocked aggregation AChR induced by agronin and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as staurosporin are demonstrated to block aggregation AChR induced by agrone and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since Mutations at site 3 splice has been shown to blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since a positive regulator in the glucocorticoid signal pathway has been shown to block the degradation of GR and induced a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since a positive regulator in the glucocorticoid signal pathway has been shown to blocked the degradation of GR and induce a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since a positive regulator in the glucocorticoid signal pathway is shown to block the degradation of GR and induce a GR elevation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of UP.1 on human progenitors CD34+ before this regulation has been shown to blocked formation of myeloid colonies (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since sporin has been shown to block agrona-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since sporin has been shown to blocked aggregation and phosphorylation AChR induced in agro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since sporin has been shown to blocked agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since sporin is shown to block agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to block agrena-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to block agrona-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to blocked aggregation and phosphorylation of AChR induced by aggron (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to blocked agrona-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to blocked agronin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin is shown to block aggregation and phosphorylation of AChR induced by aggron (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin is shown to block agrinin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin is shown to block agronin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin is shown to block grouping and phosphorylation AChR induced in agro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>Mutations at site 3 splice can block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>Mutations at site 3 splice has blocked step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>Mutations at site 3 splice is able to block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>Mutations at site 3 splice is more specific for the distinction between different RNA polymerases, because it blocked step II (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>Mutations at site 3 splice is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of step II before the 3-slice site recognition.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>Mutations at site 3 splice that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>Mutations at site 3 splice will block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>Mutations at site 3 splice would block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>Mutations at the site of 3 splice is able to block step II.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>Mutations at the site of 3 splice is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of step II before the 3-slice site recognition.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>Mutations at the site of 3 splice that are able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>Mutations at the site of 3 splice that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>Mutations at the site of 3 splice that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>Mutations at the site of 3 splice that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>Mutations at the site of 3 splice would block step II.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>Mutations in cut-off site 3 is more specific for the distinction between different RNA polymerases, since step II is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>Mutations in cut-off site 3 is more specific for the distinction between different RNA polymerases, since step II is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>Mutations in cut-off site 3 is more specific to distinguish between different RNA polymerases because it is able to block step II (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>Mutations in cut-off site 3 was able to block step II.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>Mutations in site 3 splice can block step II.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>Mutations in site 3 splice is more specific for the distinction between different RNA polymerases, as it can block step II (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>Mutations in site 3 splice is more specific for the distinction between different RNA polymerases, since step II was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>Mutations in site 3 splice may have blocked step II.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>Mutations in site 3 splice was believed to block step II.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>Mutations in site 3 splice will block step II.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>Mutations in the 3 splice site has blocked step II.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>Mutations in the 3 splice site may block step II.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>Mutations in the 3 splice site that are specifically shown to block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>Mutations in the 3 splice site that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and Mutations at the site of 3 splice may block step II.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and a positive regulator in the glucocorticoid signal pathway has been shown to block the degradation of GR and induced a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and a positive regulator in the glucocorticoid signal pathway may block the degradation of GR and induces a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of UP.1 on human progenitors CD34+ before this regulation may block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and sporin has been shown to block agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and sporin may block aggregation and phosphorylation AChR induced in agro.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and staurosporin may block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and staurosporin may block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and a positive regulator in the glucocorticoid signal pathway has blocked the degradation of GR and the induction of a GR lift.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and inhibition of PU.1 function in CD34+ human progenitors prior to this regulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and staurosporin has blocked aggregation and phosphorylation of AChR induced by agrine.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and staurosporin has blocked agrena-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and staurosporin has blocked agrin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and staurosporin has blocked agronin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and positive regulation in the signaling pathway of glucocorticoids is shown to have blocked degradation of GR and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and sporin is shown to have blocked agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and staurosporin is shown to have blocked agrena-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and staurosporin is shown to have blocked grouping and phosphorylation AChR induced in agro.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid and A1 lineages (formation of myeloid colonies) is thought to be blocked by Mutations at the site of 3 splice.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid and A1 lineages (formation of myeloid colonies) is thought to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid and A1 lineages (formation of myeloid colonies) is thought to be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and Mutations in cut-off site 3 is shown to block step II.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of UP.1 on human progenitors CD34+ before this regulation can block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and sporin can block aggregation and phosphorylation AChR induced in agro.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and sporin is shown to block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin can block aggregation AChR induced by agronin and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin can block aggregation and phosphorylation of AChR induced by agrine.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin can block agrinin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin is shown to block agrena-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin is shown to block agrenin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin is shown to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin is shown to block argon-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and Mutations at site 3 splice will block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and aggregation AChR induced by agronin and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and aggregation and phosphorylation AChR induced in agro can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and agrona-induced AChR grouping and phosphorylation can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and degradation of GR and induction of GR elevation can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of UP.1 on the CD34+ human progenitors before this regulation will block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and mutations at the 3rd splice site will block step II.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and positive regulation in the signaling pathway of glucocorticoids will block degradation of GR and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and sporin will block aggregation and phosphorylation AChR induced in agro.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin will block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and staurosporin will block grouping and phosphorylation AChR induced in agro.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and step II can be blocked by Mutations in site 3 splice.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and the degradation of GR and induces a GR elevation can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and GR degradation and induction of GR elevation is blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and agrin-induced AChR grouping and phosphorylation is blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and argon-induced AChR grouping and phosphorylation is blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>PU.1 is updated during multi-potential parent engagement with the myeloid and A1 lineages (formation of myeloid colonies) can be blocked by Mutations in the 3 splice site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and staurosporin is able to block aggregation AChR induced by agronin and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and staurosporin is able to block arg-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and aggregation and phosphorylation of AChR induced by agrine will be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and agrin-induced AChR grouping and phosphorylation will be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and agrine-induced AChR and phosphorylation will be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and argon-induced AChR grouping and phosphorylation will be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and step II will be blocked by Mutations at site 3 splice.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and step II will be blocked by Mutations in site 3 splice.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and Mutations at the site of 3 splice blocked step II.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of PU.1 function in CD34+ human progenitors prior to this regulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of UP.1 on the CD34+ human progenitors before this regulation blocked formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and mutations at the 3rd splice site blocked step II.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and staurosporin blocked aggregation AChR induced by agronin and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and staurosporin blocked argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and staurosporin blocked phosphorylation and AChR cluster induced by agronin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Mutations at the site of 3 splice cannot block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Mutations in the 3 splice site cannot block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and staurosporin cannot block arg-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and a positive regulator in the glucocorticoid signal pathway does not block the degradation of GR and the induction of a GR lift, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and sporin does not block agrine-induced AChR and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and staurosporin does not block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and staurosporin does not block arg-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Mutations in site 3 splice is not able to block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and Mutations in the 3 splice site is not able to block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and positive regulation in the signaling pathway of glucocorticoids is not able to block degradation of GR and induce elevation of GR, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and sporin is not able to block AChR and arrhine-induced phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway cannot block the degradation of GR and induce a GR elevation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and sporin cannot block AChR and arrhine-induced phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and staurosporin cannot block aggregation and phosphorylation of AChR induced by aggron, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and staurosporin cannot block agrinin-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and aggregation and phosphorylation of AChR induced by aggron cannot be blocked by sturosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and agrenin-induced AChR grouping and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and agrin-induced AChR clustering and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and agrin-induced AChR grouping and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and agrin-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and agrona-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and arg-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and argon-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of UP.1 on the CD34+ human progenitors before this regulation does not block formation of myeloid colonies, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that agrin-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that agrinin-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that agrona-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that formation of myeloid colonies is not blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and phosphorylation and AChR cluster induced by agronin cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and positive regulation in the signaling pathway of glucocorticoids does not block degradation of GR and induction of GR elevation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and sporin does not block agrine-induced AChR and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin does not block AChR and arrhine-induced phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin does not block agrena-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin does not block agrenin-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin does not block arg-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin does not block phosphorylation and AChR cluster induced by agronin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and step II cannot be blocked by Mutations in the 3 splice site, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and sturosporin does not block aggregation and phosphorylation of AChR induced by aggron, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and the degradation of GR and induce a GR elevation is not blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and the degradation of GR and induces a GR elevation cannot be blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and GR degradation and induction of GR elevation is not blocked by positive regulation in the signaling pathway of glucocorticoids, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and aggregation AChR induced by agronin and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and aggregation and phosphorylation of AChR induced by aggron cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and agrenin-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and agrenin-induced AChR grouping and phosphorylation is not capable of being blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and agrona-induced AChR grouping and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and agrona-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and argon-induced AChR grouping and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and formation of myeloid colonies is not blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that agrin-induced AChR grouping and phosphorylation is not blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II is not capable of being blocked by Mutations at site 3 splice, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and step II is not capable of being blocked by mutations at the 3rd splice site, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the degradation of GR and induced a GR elevation cannot be blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and positive regulation in the signaling pathway of glucocorticoids has not blocked degradation of GR and induction of GR elevation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin has not blocked argon-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway will not block the degradation of GR and induced a GR elevation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway will not block the degradation of GR and the induction of a GR lift, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and positive regulation in the signaling pathway of glucocorticoids will not block degradation of GR and induce elevation of GR, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin will not block agrin-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin will not block grouping and phosphorylation AChR induced in agro, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and a positive regulator in the glucocorticoid signal pathway is not able to block the degradation of GR and induced a GR elevation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and staurosporin is not able to block aggregation and phosphorylation of AChR induced by agrine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and staurosporin is not able to block agrine-induced AChR and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Mutations at site 3 splice did not blocked step II, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and a positive regulator in the glucocorticoid signal pathway did not blocked the degradation of GR and induced a GR elevation, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of PU.1 function in CD34+ human progenitors prior to this regulation did not blocked myeloid colony formation, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and mutations at the 3rd splice site did not blocked step II, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and staurosporin did not blocked arg-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and Mutations in site 3 splice does not block step II, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and aggregation and phosphorylation of AChR induced by aggron is not able to be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and degradation of GR and induce elevation of GR is not able to be blocked by positive regulation in the signaling pathway of glucocorticoids, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>Step II can be specifically blocked by Mutations in cut-off site 3 that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-slice site.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>Step II can be specifically blocked by positive regulation in the signaling pathway of glucocorticoids that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of GR degradation and induction of GR elevation before the recognition of the 3-slice site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>Step II can be specifically blocked by sporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of agrine-induced AChR and phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>Step II can be specifically blocked by sporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of agrona-induced AChR grouping and phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>Step II can be specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of aggregation AChR induced by agronin and phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>Step II can be specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of agrena-induced AChR grouping and phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>Step II can be specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of agrinin-induced AChR grouping and phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>Step II can be specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) before the recognition of the 3-slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>Step II is believed to be specifically blocked for Mutations in site 3 splice that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>Step II is believed to be specifically blocked for sporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of AChR and arrhine-induced phosphorylation before recognition of the site of 3 cuts.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>Step II is believed to be specifically blocked for sporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of agrine-induced AChR and phosphorylation before recognition of the site of 3 cuts.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>Step II is believed to be specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of agronin-induced AChR grouping and phosphorylation before recognition of the site of 3 cuts.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>Step II is specifically blocked by Mutations at site 3 splice that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of step II before the recognition of site 3.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>Step II is specifically blocked by Mutations in cut-off site 3 that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of step II before the recognition of site 3.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>Step II is specifically blocked by a positive regulator in the glucocorticoid signal pathway that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of the degradation of GR and induced a GR elevation before the recognition of site 3.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>Step II is specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of AChR and arrhine-induced phosphorylation before the recognition of site 3.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>Step II is specifically blocked by staurosporin that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of agrin-induced AChR clustering and phosphorylation before the recognition of site 3.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>Step II is specifically blocked for Mutations at the site of 3 splice that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>Step II is specifically blocked for a positive regulator in the glucocorticoid signal pathway that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of the degradation of GR and induce a GR elevation before recognition of the site of 3 cuts.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>Step II is specifically blocked for inhibition of UP.1 on human progenitors CD34+ before this regulation that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of formation of myeloid colonies before recognition of the site of 3 cuts.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>Step II is specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of agrin-induced AChR clustering and phosphorylation before recognition of the site of 3 cuts.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>Step II is specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of agrine-induced AChR and phosphorylation before recognition of the site of 3 cuts.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>Step II is specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) before recognition of the site of 3 cuts.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>Step II was specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of agrin-induced AChR grouping and phosphorylation before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>Step II was specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>Step II was specifically blocked for staurosporin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of phosphorylation and AChR cluster induced by agronin before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>Step II was specifically blocked for sturosporin that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of aggregation and phosphorylation of AChR induced by aggron before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>The AChR and arrhine-induced phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin may have blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>The AChR and arrhine-induced phosphorylation with antibodies for phosphopeptide Y553 is specific, since sporin blocked labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>The AChR and arrhine-induced phosphorylationing of antibodies in the Y553 phosphopeptide is specific, since sporin will block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>The AChR and arrhine-induced phosphorylationling of antibodies in the Y553 phosphopeptide is specific, since staurosporin is able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>The GR degradation and induction of GR elevation of antibodies in the Y553 phosphopeptide is specific, since positive regulation in the signaling pathway of glucocorticoids may block labelling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>The GR degradation and induction of GR elevation with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>The GR degradation and induction of GR elevation with antibodies for phosphopeptide Y553 is specific, since positive regulation in the signaling pathway of glucocorticoids may have blocked labelling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>The Mutations in site 3 splice that is able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>The aggregation AChR induced by agrone and phosphorylation with antibodies for phosphopeptide Y553 is specific, since staurosporin will block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>The aggregation AChR induced by agronin and phosphorylationling of antibodies in the Y553 phosphopeptide is specific, since staurosporin is able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>The aggregation and phosphorylation AChR induced in agro with antibodies to phosphopeptide Y553 is specific, since sporin is able to block labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>The aggregation and phosphorylation AChR induced in agro with antibodies to phosphopeptide Y553 is specific, since sporin may block labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>The aggregation and phosphorylation AChR induced in agroling of antibodies in the Y553 phosphopeptide is specific, since sporin is able to block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>The aggregation and phosphorylation of AChR induced by aggron of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>The aggregation and phosphorylation of AChR induced by aggron of antibodies in the Y553 phosphopeptide is specific, since staurosporin may have blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>The aggregation and phosphorylation of AChR induced by aggron with antibodies against phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>The aggregation and phosphorylation of AChR induced by aggron with antibodies for phosphopeptide Y553 is specific, since staurosporin blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>The aggregation and phosphorylation of AChR induced by aggron with antibodies for phosphopeptide Y553 is specific, since staurosporin will block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>The aggregation and phosphorylation of AChR induced by aggroning of antibodies in the Y553 phosphopeptide is specific, since sturosporin will block label.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>The aggregation and phosphorylation of AChR induced by agrine of antibodies in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>The agrena-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin may have blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>The agrena-induced AChR grouping and phosphorylation with antibodies against phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>The agrena-induced AChR grouping and phosphorylation with antibodies to phosphopeptide Y553 is specific, since staurosporin is able to block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>The agrena-induced AChR grouping and phosphorylationing of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>The agrena-induced AChR grouping and phosphorylationling of antibodies in the Y553 phosphopeptide is specific, since staurosporin is able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>The agrenin-induced AChR grouping and phosphorylation with antibodies to phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>The agrin-induced AChR clustering and phosphorylation with antibodies against phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>The agrin-induced AChR clustering and phosphorylation with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>The agrin-induced AChR clustering and phosphorylation with antibodies to phosphopeptide Y553 is specific, since staurosporin is able to block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>The agrin-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin may have blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>The agrin-induced AChR grouping and phosphorylation with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>The agrin-induced AChR grouping and phosphorylation with antibodies for phosphopeptide Y553 is specific, since staurosporin will block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>The agrine-induced AChR and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>The agrinin-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>The agrona-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since sporin may have blocked labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>The agrona-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>The agrona-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>The agrona-induced AChR grouping and phosphorylation with antibodies for phosphopeptide Y553 is specific, since sporin blocked labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>The agrona-induced AChR grouping and phosphorylation with antibodies to phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>The agrona-induced AChR grouping and phosphorylationing of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>The agrona-induced AChR grouping and phosphorylationling of antibodies in the Y553 phosphopeptide is specific, since staurosporin is able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>The agronin-induced AChR grouping and phosphorylation with antibodies against phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>The antibody AChR and arrhine-induced phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>The antibody AChR and arrhine-induced phosphorylation for the phosphopeptide Y553 was specific, since labeling can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>The antibody AChR and arrhine-induced phosphorylation in the Y553 phosphopeptide is specific, since labelling can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>The antibody AChR and arrhine-induced phosphorylation in the Y553 phosphopeptide was specific, since labeling can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>The antibody AChR and arrhine-induced phosphorylationing for the phosphopeptide Y553 was specific, since label can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>The antibody AChR and arrhine-induced phosphorylationing in the Y553 phosphopeptide was specific, as sporin was able to block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>The antibody AChR and arrhine-induced phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin was able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>The antibody AChR and arrhine-induced phosphorylationing in the Y553 phosphopeptide was specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>The antibody AChR and arrhine-induced phosphorylationling in the Y553 phosphopeptide is specific, since label can be blocked by sporin.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>The antibody GR degradation and induction of GR elevationing for the phosphopeptide Y553 was specific, since label can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>The antibody aggregation AChR induced by agrone and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin could block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>The antibody aggregation AChR induced by agronin and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin may have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>The antibody aggregation AChR induced by agronin and phosphorylation for the phosphopeptide Y553 was specific, since labeling was able to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>The antibody aggregation AChR induced by agronin and phosphorylationing in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>The antibody aggregation and phosphorylation AChR induced in agro for the phosphopeptide Y553 was specific, as sporin could have blocked labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>The antibody aggregation and phosphorylation AChR induced in agro for the phosphopeptide Y553 was specific, as sporin was able to block labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>The antibody aggregation and phosphorylation AChR induced in agro in the Y553 phosphopeptide is specific, since sporin may block labelling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>The antibody aggregation and phosphorylation AChR induced in agroing in the Y553 phosphopeptide was specific, since sporin would have blocked label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, as staurosporin could block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, as staurosporin may block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron for the phosphopeptide Y553 was specific, since labeling was blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron in the Y553 phosphopeptide is specific, since labelling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron in the Y553 phosphopeptide was specific, as staurosporin could block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggron in the Y553 phosphopeptide was specific, since labeling can be blocked by sturosporin.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggroning for the phosphopeptide Y553 was specific, as staurosporin may block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggroning in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggroning in the Y553 phosphopeptide is specific, since sturosporin blocked label.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggroning in the Y553 phosphopeptide was specific, as staurosporin would block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggroning in the Y553 phosphopeptide was specific, as sturosporin was able to block label.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>The antibody aggregation and phosphorylation of AChR induced by aggronling in the Y553 phosphopeptide is specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>The antibody aggregation and phosphorylation of AChR induced by agrineing in the Y553 phosphopeptide was specific, as staurosporin could block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>The antibody agrena-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>The antibody agrena-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, since staurosporin could have blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin was able to block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylation in the Y553 phosphopeptide was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylationing for the phosphopeptide Y553 was specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin could block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>The antibody agrenin-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin would block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>The antibody agrin-induced AChR clustering and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>The antibody agrin-induced AChR clustering and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin would have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>The antibody agrin-induced AChR clustering and phosphorylation for the phosphopeptide Y553 was specific, since labeling was able to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>The antibody agrin-induced AChR clustering and phosphorylationling in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>The antibody agrin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>The antibody agrin-induced AChR grouping and phosphorylation in the Y553 phosphopeptide was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>The antibody agrin-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>The antibody agrin-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, since staurosporin could have blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>The antibody agrine-induced AChR and phosphorylation for the phosphopeptide Y553 was specific, as sporin would block labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>The antibody agrine-induced AChR and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin was able to block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>The antibody agrine-induced AChR and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin could block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>The antibody agrine-induced AChR and phosphorylationing in the Y553 phosphopeptide was specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>The antibody agrine-induced AChR and phosphorylationling in the Y553 phosphopeptide is specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>The antibody agrinin-induced AChR grouping and phosphorylationling in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>The antibody agrona-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>The antibody agrona-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin would block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>The antibody agrona-induced AChR grouping and phosphorylation in the Y553 phosphopeptide is specific, since sporin blocked labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>The antibody agrona-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide is specific, since sporin blocked label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>The antibody agrona-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, as sporin would block label.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>The antibody agrona-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin was able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>The antibody agronin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>The antibody agronin-induced AChR grouping and phosphorylation in the Y553 phosphopeptide is specific, since staurosporin blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>The antibody agronin-induced AChR grouping and phosphorylation in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>The antibody agronin-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, as staurosporin would block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>The antibody arg-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin was able to block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>The antibody arg-induced AChR grouping and phosphorylationing for the phosphopeptide Y553 was specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>The antibody argon-induced AChR grouping and phosphorylation in the Y553 phosphopeptide was specific, as staurosporin could block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>The antibody argon-induced AChR grouping and phosphorylation in the Y553 phosphopeptide was specific, as staurosporin would block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>The antibody argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) in the Y553 phosphopeptide was specific, as staurosporin would block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>The antibody argon-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, since label can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>The antibody argon-induced AChR grouping and phosphorylationing in the Y553 phosphopeptide was specific, since staurosporin would have blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>The antibody degradation of GR and induction of GR elevation for the phosphopeptide Y553 was specific, as positive regulation in the signaling pathway of glucocorticoids may have blocked labeling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>The antibody degradation of GR and induction of GR elevation for the phosphopeptide Y553 was specific, as positive regulation in the signaling pathway of glucocorticoids was able to block labeling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>The antibody degradation of GR and induction of GR elevationing in the Y553 phosphopeptide was specific, as positive regulation in the signaling pathway of glucocorticoids could block label.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>The antibody degradation of GR and induction of GR elevationing in the Y553 phosphopeptide was specific, since positive regulation in the signaling pathway of glucocorticoids would have blocked label.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>The antibody degradation of GR and induction of GR elevationling in the Y553 phosphopeptide is specific, since positive regulation in the signaling pathway of glucocorticoids blocked label.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>The antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, as inhibition of UP.1 on the CD34+ human progenitors before this regulation may block labeling.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>The antibody formation of myeloid colonies for the phosphopeptide Y553 was specific, since labeling was able to be blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>The antibody formation of myeloid colonies in the Y553 phosphopeptide was specific, as inhibition of UP.1 on human progenitors CD34+ before this regulation could block labeling.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>The antibody formation of myeloid colonies in the Y553 phosphopeptide was specific, as inhibition of UP.1 on human progenitors CD34+ before this regulation would block labeling.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>The antibody formation of myeloid colonies in the Y553 phosphopeptide was specific, since labeling can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>The antibody formation of myeloid coloniesing for the phosphopeptide Y553 was specific, as inhibition of UP.1 on the CD34+ human progenitors before this regulation may block label.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>The antibody formation of myeloid coloniesing in the Y553 phosphopeptide is specific, since inhibition of UP.1 on human progenitors CD34+ before this regulation blocked label.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>The antibody formation of myeloid coloniesing in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function on human progenitors CD34+ before this regulation would block label.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>The antibody formation of myeloid coloniesing in the Y553 phosphopeptide was specific, as inhibition of the PU.1 function on the CD34+ human progenitors before this regulation would block label.</text>
                    <arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>The antibody formation of myeloid coloniesling in the Y553 phosphopeptide is specific, since label can be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>The antibody grouping and phosphorylation AChR induced in agro for the phosphopeptide Y553 was specific, as staurosporin would have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>The antibody grouping and phosphorylation AChR induced in agro in the Y553 phosphopeptide is specific, since labelling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>The antibody grouping and phosphorylation AChR induced in agroing for the phosphopeptide Y553 was specific, as staurosporin may block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>The antibody grouping and phosphorylation AChR induced in agroling in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>The antibody in vitro merozoite invasion in the Y553 phosphopeptide was specific, since labeling can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>The antibody in vitro merozoite invasionling in the Y553 phosphopeptide is specific, since label can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>The antibody invasion of merozoite in vitro in the Y553 phosphopeptide was specific, as antibodies to RAP1 could block labeling.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as a positive regulator in the glucocorticoid signal pathway may block the degradation of GR and the induction of a GR lift.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as inhibition of PU.1 function in CD34+ human progenitors prior to this regulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as positive regulation in the signaling pathway of glucocorticoids may block GR degradation and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as sporin may block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as staurosporin may block agrinin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as staurosporin may block arg-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as staurosporin may block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, as sturosporin may block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since GR degradation and induction of GR elevation can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since agrin-induced AChR grouping and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since formation of myeloid colonies can be blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since step II can be blocked by Mutations in cut-off site 3.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and induces a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since positive regulation in the signaling pathway of glucocorticoids blocked degradation of GR and induce elevation of GR.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since staurosporin blocked aggregation AChR induced by agronin and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since staurosporin blocked aggregation and phosphorylation of AChR induced by agrine.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>The antibody labeling in the Y553 phosphopeptide is specific, since staurosporin blocked agronin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as Mutations at the site of 3 splice could block step II.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as Mutations in cut-off site 3 would block step II.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as Mutations in the 3 splice site would block step II.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as staurosporin could block aggregation and phosphorylation of AChR induced by agrine.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as staurosporin would block aggregation AChR induced by agrone and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as staurosporin would block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as staurosporin would block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since aggregation and phosphorylation of AChR induced by aggron can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since agrinin-induced AChR grouping and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since agronin-induced AChR grouping and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since formation of myeloid colonies can be blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, since step II can be blocked by Mutations at the site of 3 splice.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since argon-induced AChR grouping and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since degradation of GR and induce elevation of GR can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since degradation of GR and induction of GR elevation can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>The antibody labelling in the Y553 phosphopeptide is specific, since step II can be blocked by Mutations in the 3 splice site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>The antibody labelling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>The antibody labelling in the Y553 phosphopeptide was specific, since labeling can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>The antibody labellinging in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide could block label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU.1 function in CD34+ human progenitors prior to this regulation could have blocked labeling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, as inhibition of PU.1 function in CD34+ human progenitors prior to this regulation may block labeling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>The antibody myeloid colony formation in the Y553 phosphopeptide was specific, as inhibition of PU.1 function in CD34+ human progenitors prior to this regulation could block labeling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>The antibody myeloid colony formationling in the Y553 phosphopeptide is specific, since label can be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>The antibody phosphorylation and AChR cluster induced by agronin for the phosphopeptide Y553 was specific, as staurosporin may block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>The antibody phosphorylation and AChR cluster induced by agronin for the phosphopeptide Y553 was specific, as staurosporin was able to block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>The antibody phosphorylation and AChR cluster induced by agronin in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>The antibody phosphorylation and AChR cluster induced by agroninling in the Y553 phosphopeptide is specific, since staurosporin blocked label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as Mutations at site 3 splice could have blocked labeling.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as Mutations in site 3 splice would have blocked labeling.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, as mutations at the 3rd splice site would block labeling.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling can be blocked by Mutations at the site of 3 splice.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling can be blocked by mutations at the 3rd splice site.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was able to be blocked by Mutations in cut-off site 3.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was blocked by Mutations in site 3 splice.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was blocked by Mutations in the 3 splice site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>The antibody step II in the Y553 phosphopeptide is specific, since Mutations in the 3 splice site blocked labeling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>The antibody step II in the Y553 phosphopeptide is specific, since Mutations in the 3 splice site may block labelling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>The antibody step II in the Y553 phosphopeptide was specific, as Mutations at site 3 splice would block labeling.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>The antibody step II in the Y553 phosphopeptide was specific, as Mutations at the site of 3 splice could block labeling.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>The antibody step II in the Y553 phosphopeptide was specific, as Mutations in the 3 splice site could block labeling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>The antibody step II in the Y553 phosphopeptide was specific, since labeling can be blocked by Mutations in cut-off site 3.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, as Mutations at site 3 splice could block label.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, as Mutations in cut-off site 3 could block label.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, as Mutations in the 3 splice site would block label.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, as mutations at the 3rd splice site would block label.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, since Mutations in site 3 splice would have blocked label.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>The antibody step IIing in the Y553 phosphopeptide was specific, since mutations at the 3rd splice site would have blocked label.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>The antibody the degradation of GR and induce a GR elevation for the phosphopeptide Y553 was specific, as a positive regulator in the glucocorticoid signal pathway may have blocked labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>The antibody the degradation of GR and induce a GR elevation in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway blocked labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>The antibody the degradation of GR and induce a GR elevation in the Y553 phosphopeptide was specific, as a positive regulator in the glucocorticoid signal pathway would block labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>The antibody the degradation of GR and induce a GR elevationing in the Y553 phosphopeptide was specific, since a positive regulator in the glucocorticoid signal pathway could have blocked label.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>The antibody the degradation of GR and induce a GR elevationing in the Y553 phosphopeptide was specific, since label can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>The antibody the degradation of GR and induced a GR elevationing in the Y553 phosphopeptide was specific, as a positive regulator in the glucocorticoid signal pathway could block label.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>The antibody the degradation of GR and induced a GR elevationing in the Y553 phosphopeptide was specific, since label can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>The antibody the degradation of GR and induces a GR elevation for the phosphopeptide Y553 was specific, as a positive regulator in the glucocorticoid signal pathway may block labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>The antibody the degradation of GR and induces a GR elevation for the phosphopeptide Y553 was specific, as a positive regulator in the glucocorticoid signal pathway would have blocked labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>The antibody the degradation of GR and induces a GR elevation for the phosphopeptide Y553 was specific, since labeling was blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>The antibody the degradation of GR and induces a GR elevation in the Y553 phosphopeptide was specific, as a positive regulator in the glucocorticoid signal pathway would block labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>The antibody the degradation of GR and induces a GR elevationing in the Y553 phosphopeptide was specific, as a positive regulator in the glucocorticoid signal pathway could block label.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>The arg-induced AChR grouping and phosphorylation with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>The argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) of antibodies in the Y553 phosphopeptide is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>The argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>The argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) with antibodies to phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>The argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)ing of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>The argon-induced AChR grouping and phosphorylation of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>The degradation of GR and induce elevation of GR with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>The degradation of GR and induce elevation of GR with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by positive regulation in the signaling pathway of glucocorticoids.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>The degradation of GR and induction of GR elevation with antibodies for phosphopeptide Y553 is specific, since positive regulation in the signaling pathway of glucocorticoids will block labelling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>The formation of myeloid colonies of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on human progenitors CD34+ before this regulation will block labeling.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>The formation of myeloid colonies with antibodies against phosphopeptide Y553 is specific, since inhibition of UP.1 on human progenitors CD34+ before this regulation may block labelling.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>The formation of myeloid colonies with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>The formation of myeloid colonies with antibodies for phosphopeptide Y553 is specific, since inhibition of UP.1 on human progenitors CD34+ before this regulation blocked labelling.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>The formation of myeloid colonies with antibodies for phosphopeptide Y553 is specific, since inhibition of UP.1 on the CD34+ human progenitors before this regulation will block labelling.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>The formation of myeloid colonies with antibodies to phosphopeptide Y553 is specific, since inhibition of UP.1 on the CD34+ human progenitors before this regulation may block labelling.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>The formation of myeloid coloniesing of antibodies in the Y553 phosphopeptide is specific, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation will block label.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>The formation of myeloid coloniesing of antibodies in the Y553 phosphopeptide is specific, since inhibition of UP.1 on the CD34+ human progenitors before this regulation will block label.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>The formation of myeloid coloniesing of antibodies in the Y553 phosphopeptide is specific, since inhibition of the PU.1 function on human progenitors CD34+ before this regulation will block label.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>The grouping and phosphorylation AChR induced in agro with antibodies for phosphopeptide Y553 is specific, since staurosporin blocked labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>The grouping and phosphorylation AChR induced in agro with antibodies to phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since Mutations at site 3 splice will block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and induce a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and induced a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since inhibition of PU.1 function in CD34+ human progenitors prior to this regulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since positive regulation in the signaling pathway of glucocorticoids will block GR degradation and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since sporin will block aggregation and phosphorylation AChR induced in agro.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since sporin will block agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block arg-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>The labeling of antibodies in the Y553 phosphopeptide is specific, since sturosporin will block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>The labelling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>The myeloid colony formation with antibodies against phosphopeptide Y553 is specific, since inhibition of PU.1 function in CD34+ human progenitors prior to this regulation may block labelling.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>The myeloid colony formation with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>The myeloid colony formation with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>The phosphorylation and AChR cluster induced by agronin of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>The phosphorylation and AChR cluster induced by agronin with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>The phosphorylation and AChR cluster induced by agronin with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>The phosphorylation and AChR cluster induced by agronin with antibodies to phosphopeptide Y553 is specific, since staurosporin may block labelling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>The phosphorylation and AChR cluster induced by agronining of antibodies in the Y553 phosphopeptide is specific, since staurosporin will block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>The positive regulation in the signaling pathway of glucocorticoids that is able to specifically block GR degradation and induction of GR elevation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>The staurosporin that is able to specifically block aggregation and phosphorylation of AChR induced by agrine does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>The staurosporin that is able to specifically block agrena-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since Mutations at the site of 3 splice may have blocked labelling.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since Mutations in cut-off site 3 may block labelling.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since Mutations in site 3 splice will block labeling.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since Mutations in the 3 splice site may have blocked labelling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by Mutations in the 3 splice site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>The step II of antibodies in the Y553 phosphopeptide is specific, since mutations at the 3rd splice site may block labelling.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>The step II with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by Mutations at the site of 3 splice.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>The step II with antibodies for phosphopeptide Y553 is specific, since Mutations at the site of 3 splice may have blocked labelling.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>The step II with antibodies for phosphopeptide Y553 is specific, since Mutations in the 3 splice site will block labelling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since Mutations at site 3 splice may block labelling.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since Mutations in site 3 splice is able to block labelling.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>The step II with antibodies to phosphopeptide Y553 is specific, since Mutations in the 3 splice site may block labelling.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>The step IIing of antibodies in the Y553 phosphopeptide is specific, since Mutations in the 3 splice site will block label.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>The the degradation of GR and induce a GR elevation with antibodies to phosphopeptide Y553 is specific, since a positive regulator in the glucocorticoid signal pathway is able to block labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>The the degradation of GR and induced a GR elevation of antibodies in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway may have blocked labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>The the degradation of GR and induced a GR elevation with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>The the degradation of GR and induced a GR elevation with antibodies for phosphopeptide Y553 is specific, since a positive regulator in the glucocorticoid signal pathway blocked labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>The the degradation of GR and induced a GR elevationling of antibodies in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway is able to block label.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>The the degradation of GR and induces a GR elevation with antibodies against phosphopeptide Y553 is specific, since a positive regulator in the glucocorticoid signal pathway may block labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>The the degradation of GR and induces a GR elevation with antibodies for phosphopeptide Y553 is specific, since a positive regulator in the glucocorticoid signal pathway blocked labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>The the degradation of GR and the induction of a GR lift of antibodies in the Y553 phosphopeptide is specific, since a positive regulator in the glucocorticoid signal pathway may have blocked labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>The the degradation of GR and the induction of a GR lift with antibodies for phosphopeptide Y553 is specific, since a positive regulator in the glucocorticoid signal pathway may have blocked labelling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>UP. 1 is activated at the start of the multipotential parent commitment for myeloid and A1 lineages (the formation of myeloid colonies) will be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>UP. 1 is activated at the start of the multipotential parent commitment for myeloid and A1 lineages (the formation of myeloid colonies) will be blocked by mutations at the 3rd splice site.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and AChR and arrhine-induced phosphorylation is thought to be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and step II is thought to be blocked by Mutations in site 3 splice.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and the induction of a GR lift.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>a positive regulator in the glucocorticoid signal pathway could block the degradation of GR and induces a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>a positive regulator in the glucocorticoid signal pathway has blocked the degradation of GR and the induction of a GR lift.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for the distinction between different RNA polymerases, as it can blocks the degradation of GR and the induction of a GR lift (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for the distinction between different RNA polymerases, because it blocked the degradation of GR and the induction of a GR lift (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for the distinction between different RNA polymerases, since the degradation of GR and induces a GR elevation is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific to distinguish between different RNA polymerases because the degradation of GR and induce a GR elevation was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific to distinguish between different RNA polymerases because the degradation of GR and the induction of a GR lift can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific to distinguish between different RNA polymerases because the degradation of GR and the induction of a GR lift is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>a positive regulator in the glucocorticoid signal pathway is thought to block the degradation of GR and induced a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>a positive regulator in the glucocorticoid signal pathway that are able to specifically block the degradation of GR and induces a GR elevation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induces a GR elevation</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>a positive regulator in the glucocorticoid signal pathway that are believed to specifically block the degradation of GR and induced a GR elevation does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and induce a GR elevation.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>aggregation AChR induced by agronin and phosphorylation is blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>aggregation and phosphorylation of AChR induced by aggron was blocked by sturosporin.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>agrin-induced AChR grouping and phosphorylation was blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>arg-induced AChR grouping and phosphorylation can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>formation of myeloid colonies has been blocked by inhibition of UP.1 on human progenitors CD34+ before this regulation.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this regulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this regulation is more specific for the distinction between different RNA polymerases, as it can block myeloid colony formation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this regulation is more specific to distinguish between different RNA polymerases because it can block myeloid colony formation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>inhibition of PU.1 function in CD34+ human progenitors prior to this regulation that are able to specifically block myeloid colony formation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>inhibition of UP.1 on human progenitors CD34+ before this regulation is more specific to distinguish between different RNA polymerases because it can blocks formation of myeloid colonies (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>inhibition of UP.1 on human progenitors CD34+ before this regulation that are believed to specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>inhibition of UP.1 on human progenitors CD34+ before this regulation that specifically blocked formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>inhibition of UP.1 on the CD34+ human progenitors before this regulation is more specific to distinguish between different RNA polymerases because it can blocks formation of myeloid colonies (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>inhibition of UP.1 on the CD34+ human progenitors before this regulation is more specific to distinguish between different RNA polymerases because it is able to block formation of myeloid colonies (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>inhibition of UP.1 on the CD34+ human progenitors before this regulation may have blocked formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>inhibition of UP.1 on the CD34+ human progenitors before this regulation was able to block formation of myeloid colonies.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>mutations at the 3rd splice site is more specific for the distinction between different RNA polymerases, since step II was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>mutations at the 3rd splice site that are able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>mutations at the 3rd splice site will block step II.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>phosphorylation and AChR cluster induced by agronin has been blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific for the distinction between different RNA polymerases, since degradation of GR and induction of GR elevation is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific to distinguish between different RNA polymerases because degradation of GR and induction of GR elevation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific to distinguish between different RNA polymerases because it can block degradation of GR and induction of GR elevation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific to distinguish between different RNA polymerases because it can blocks GR degradation and induction of GR elevation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>positive regulation in the signaling pathway of glucocorticoids is thought to block GR degradation and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>positive regulation in the signaling pathway of glucocorticoids is thought to block degradation of GR and induce elevation of GR.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>positive regulation in the signaling pathway of glucocorticoids is thought to block degradation of GR and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>positive regulation in the signaling pathway of glucocorticoids is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of degradation of GR and induce elevation of GR before the 3-slice site recognition.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>positive regulation in the signaling pathway of glucocorticoids that are able to specifically block degradation of GR and induce elevation of GR does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>positive regulation in the signaling pathway of glucocorticoids that can specifically block degradation of GR and induce elevation of GR does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>positive regulation in the signaling pathway of glucocorticoids that can specifically block degradation of GR and induction of GR elevation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>positive regulation in the signaling pathway of glucocorticoids that specifically blocked degradation of GR and induce elevation of GR does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>positive regulation in the signaling pathway of glucocorticoids was believed to block GR degradation and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>positive regulation in the signaling pathway of glucocorticoids will block degradation of GR and induction of GR elevation.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>sporin can block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>sporin has blocked AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>sporin is more specific for the distinction between different RNA polymerases, as it can block agrona-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>sporin is more specific for the distinction between different RNA polymerases, because it blocked agrine-induced AChR and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>sporin is more specific for the distinction between different RNA polymerases, since AChR and arrhine-induced phosphorylation was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>sporin is more specific for the distinction between different RNA polymerases, since agrine-induced AChR and phosphorylation is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>sporin is more specific to distinguish between different RNA polymerases because aggregation and phosphorylation AChR induced in agro was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>sporin is more specific to distinguish between different RNA polymerases because agrona-induced AChR grouping and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>sporin is more specific to distinguish between different RNA polymerases because it can block AChR and arrhine-induced phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>sporin is more specific to distinguish between different RNA polymerases because it is able to block agrona-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>sporin is thought to block aggregation and phosphorylation AChR induced in agro.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>sporin is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of AChR and arrhine-induced phosphorylation before the 3-slice site recognition.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>sporin is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of agrine-induced AChR and phosphorylation before the 3-slice site recognition.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>sporin specifically blocking agrona-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>sporin will block agrona-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>staurosporin blocked aggregation AChR induced by agrone and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>staurosporin blocked agrin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>staurosporin blocked agrona-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>staurosporin blocked agronin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>staurosporin can block agrenin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>staurosporin can block argon-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>staurosporin could block agrinin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>staurosporin could block phosphorylation and AChR cluster induced by agronin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>staurosporin has blocked aggregation and phosphorylation of AChR induced by agrine.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>staurosporin has blocked agrenin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>staurosporin has blocked agrona-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>staurosporin has blocked phosphorylation and AChR cluster induced by agronin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, as it can block agronin-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, as it can blocks aggregation and phosphorylation of AChR induced by agrine (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, as it can blocks agrinin-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, as it can blocks argon-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, because it blocked aggregation AChR induced by agronin and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, because it blocked aggregation AChR induced by agronin and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, because it blocked aggregation and phosphorylation of AChR induced by agrine (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, because it blocked agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, because it blocked agrin-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agrena-induced AChR grouping and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agrena-induced AChR grouping and phosphorylation was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agrin-induced AChR grouping and phosphorylation is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agrona-induced AChR grouping and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agronin-induced AChR grouping and phosphorylation is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since agronin-induced AChR grouping and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>staurosporin is more specific for the distinction between different RNA polymerases, since phosphorylation and AChR cluster induced by agronin was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because aggregation AChR induced by agronin and phosphorylation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because agrin-induced AChR grouping and phosphorylation was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because agrine-induced AChR and phosphorylation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because agrine-induced AChR and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because argon-induced AChR grouping and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because argon-induced AChR grouping and phosphorylation was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it can block aggregation and phosphorylation of AChR induced by aggron (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it can block agrena-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it can block agrenin-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it can block phosphorylation and AChR cluster induced by agronin (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it can blocks aggregation and phosphorylation of AChR induced by agrine (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it is able to block aggregation AChR induced by agronin and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it is able to block agrin-induced AChR grouping and phosphorylation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>staurosporin is more specific to distinguish between different RNA polymerases because it is able to block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>staurosporin is thought to block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>staurosporin is thought to block agrinin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>staurosporin is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of agrenin-induced AChR grouping and phosphorylation before the 3-slice site recognition.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>staurosporin is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of agrine-induced AChR and phosphorylation before the 3-slice site recognition.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>staurosporin may block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>staurosporin may block agrena-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>staurosporin may block agrenin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>staurosporin may block arg-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>staurosporin may have blocked agrinin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>staurosporin may have blocked argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>staurosporin specifically blocking aggregation AChR induced by agrone and phosphorylation does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>staurosporin specifically blocking agrona-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>staurosporin specifically blocking arg-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">arg-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>staurosporin that are able to specifically block aggregation AChR induced by agrone and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>staurosporin that are able to specifically block agrin-induced AChR clustering and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>staurosporin that are able to specifically block agrin-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>staurosporin that are able to specifically block agrona-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>staurosporin that are able to specifically block phosphorylation and AChR cluster induced by agronin does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>staurosporin that are believed to specifically block agrena-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>staurosporin that are believed to specifically block agrin-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>staurosporin that are specifically shown to block AChR and arrhine-induced phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>staurosporin that are specifically shown to block phosphorylation and AChR cluster induced by agronin does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>staurosporin that can specifically block AChR and arrhine-induced phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>staurosporin that can specifically block agrin-induced AChR clustering and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>staurosporin that can specifically block agrin-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>staurosporin that can specifically block agrona-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>staurosporin that can specifically block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>staurosporin that can specifically block grouping and phosphorylation AChR induced in agro does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>staurosporin that specifically blocked aggregation and phosphorylation of AChR induced by aggron does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>staurosporin that specifically blocked agrin-induced AChR clustering and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>staurosporin that specifically blocked agrine-induced AChR and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>staurosporin that specifically blocked agrinin-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>staurosporin that specifically blocked argon-induced AChR grouping and phosphorylation does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>staurosporin that specifically blocked grouping and phosphorylation AChR induced in agro does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>staurosporin was able to block aggregation and phosphorylation of AChR induced by aggron.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>staurosporin was able to block agrenin-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>staurosporin was believed to block agrona-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>staurosporin will block agrena-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>staurosporin will block grouping and phosphorylation AChR induced in agro.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">grouping and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>staurosporin would block aggregation AChR induced by agronin and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>staurosporin would block agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>staurosporin would block argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>step II is blocked by Mutations in cut-off site 3.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>step II was blocked by Mutations in site 3 splice.</text>
                    <arg n="0">Mutations in site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>sturosporin is more specific for the distinction between different RNA polymerases, since aggregation and phosphorylation of AChR induced by aggron was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>sturosporin is more specific to distinguish between different RNA polymerases because aggregation and phosphorylation of AChR induced by aggron can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>sturosporin is more specific to distinguish between different RNA polymerases because it can block aggregation and phosphorylation of AChR induced by aggron (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>sturosporin is more specific to distinguish between different RNA polymerases because it can blocks aggregation and phosphorylation of AChR induced by aggron (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">sturosporin</arg>
                    <arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>the degradation of GR and the induction of a GR lift can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
